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University of Connecticut, 2017 
 
 
In the cell, cAMP-protein kinase A (PKA) signaling is compartmentalized. Two 
different receptor types, both utilizing cAMP and PKA as second messenger and 
signal effector, are able to convey separate signals that result in phosphorylation 
of distinct substrates. Signal compartmentation is possible primarily because of A 
Kinase Anchoring Proteins (AKAPs) that bind both PKA and a target substrate, 
effectively co-localizing them. AKAPs are also capable of binding to other 
necessary signaling components like adenylate cyclase and phosphodiesterase, 
thus enabling AKAPs to coordinate a signaling microdomain containing many of 
necessary components. In this thesis I present multiple lines of evidence 
demonstrating how AKAP7γ is able to regulate PKA phosphorylation. First, I 
show that AKAP7γ is able to self-associate, forming dimers and possibly higher 
order oligomers. I predict via computational modeling that this behavior will 
increase both the speed and magnitude of PKA signaling. Next, I demonstrate 
that AKAP7γ participates in a highly dynamic phosphorylation-state dependent 
interaction with phospholamban (PLB), and predict via computational modeling 
that this allows low concentrations of AKAP7γ to regulate phosphorylation of 
much higher concentrations of substrate. Finally I demonstrate via computational 
modeling that contrary to the widely accepted hypothesis of AKAP signaling, the  
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catalytic subunit of PKA is likely retained within the AKAP-PKA complex during 
signaling events. I further show that the structure of the complex is an important 
determinant of substrate phosphorylation. This work offers new insight into the 
function of AKAPs and offers an update to the AKAP signaling hypothesis. 
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cAMP Signaling 
In 1958, Earl Sutherland and Ted Rall reported the isolation of an unusual 
adenine ribonucleotide formed by liver in the presence of ATP, Mg2+, and 
epinephrine or glucagon (1). This unusual ribonucleotide that stimulated the 
formation of liver phosphorylase in response to epinephrine or glucagon was 
called 3,5-AMP, now known as cyclic AMP (cAMP) (2). Since their initial 
discovery, the cAMP signaling pathway has become one of the most well 
characterized signal transduction systems due to its ubiquitous presence in all 
cell types. It is now widely appreciated that many hormones and 
neurotransmitters exert their physiological functions via activation of the cAMP 
pathway and its downstream effectors. Hormone binding to seven trans-
membrane domain G protein-coupled receptors at the cell surface results in the 
activation and release of the Gαs subunit. Subsequent activation of adenylate 
cyclase (AC) by Gαs stimulates increased production of cAMP and activation of 
downstream effectors including cAMP-dependent protein kinase A (PKA), the 
guanine nucleotide exchange factor Epac, and cyclic nucleotide-gated ion 
channels. Following activation of these downstream effectors, cAMP levels are 
returned to baseline via degradation by phosphodiesterases (PDEs). 
A decade after the discovery of cAMP, Kuo and Greengard advanced the 
idea that ubiquitous cAMP dependent protein kinases mediate most, if not all 
effects of cAMP in eukaryotes (3). According to their hypothesis, the ability of a 
hormone to produce the appropriate response depends upon expression of the 
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appropriate AC-linked receptor and PKA substrates. Thus, receptor expression 
determines the sensitivity of a cell type to a particular hormone, and the presence 
of specific substrates determines the response. According to Rall, this hypothesis 
presented “the unsatisfying picture of the catalytic subunit of protein kinase 
swimming about, happily phosphorylating a variety of cellular constituents 
whether they need it or not” (4). At the time, activation of AC by hormone binding 
at the cell surface was thought to result in uniform increases in cAMP 
concentration across the cell due to the high diffusion coefficient of cAMP. Such 
increases in cAMP would lead to cell wide activation of PKA and phosphorylation 
of all PKA substrates. For cell types that express multiple receptors with separate 
downstream targets, this hypothesis did not provide a means for preventing 
cross-talk among multiple signaling pathways. Rall’s criticism regarding the 
apparent lack of substrate specificity of PKA phosphorylation is even more 
pertinent in light of recent evidence demonstrating that a single cell type may 
contain over 100 PKA substrates (5). 
In the late 1970’s evidence began to accumulate that activation of a single 
receptor type did not lead to global substrate phosphorylation, rather it caused 
phosphorylation of a specific subset of PKA substrates. The work of Keely 
demonstrated that while prostaglandin E1 (PGE1) and epinephrine both produce 
increases in cAMP and activation of PKA in the rat heart, only epinephrine 
caused a significant increase in glycogen phosphorylase activity (6). Similar work 
in adipose tissue by Honeyman and Levy demonstrated that while epinephrine, 
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isoproterenol, and glucagon produced parallel activation of glycogen 
phosphorylase and lipolysis, serotonin activated glycogen phosphorylase but 
failed to induce lipolysis (7). Hayes and Brunton demonstrated further, that 
different receptor types are not only capable of producing separate down stream 
effects, they also may not share the same pool of cAMP and PKA (8). 
Isoproterenol and PGE1 were each found to increase both production of cAMP 
and activation of PKA in the rat heart, yet isoproterenol activated glycogen 
phosphorylase and induced increased contractility while PGE1 did not. 
Importantly, stimulation with both agents had an additive effect on the production 
of cAMP and activation of PKA, but did not produce an increase in either 
glycogen phosphorylase activity or contractility compared to isoproterenol alone. 
These findings formed the basis of the idea of compartmentation, in which it was 
hypothesized that each hormone activates a discrete pool of PKA. This 
hypothesis is supported by the findings of Corbin et al, who demonstrated that 
specific isozymes of PKA are distributed within distinct cellular compartments (9), 
thus providing a potential mechanism for compartmentation. By associating with 
a specific PKA isozyme, a receptor may target only the substrates associated 
with the compartment of the given isozyme. While Hayes and Brunton were 
largely correct, the mechanism that enabled anchoring of specific PKA isozymes 
to distinct compartments remained unknown. This role is fulfilled by A-Kinase 
anchoring proteins (AKAPs). 
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A-Kinase Anchoring Proteins 
Protein kinase A is a broad specificity serine/threonine kinase consisting 
of a regulatory subunit (R) dimer and two catalytic subunits (C). The binding of 
two molecules of cAMP to each regulatory subunit induces a conformational shift 
that releases the active C subunits (10). Although each of the two subunits 
comprising the PKA heterotetramer has several isoforms, their diversity is limited 
in comparison to the number of receptors utilizing the cAMP-PKA signaling 
pathway. There are four isoforms of the regulatory subunit (RIα, RIβ, RIIα and 
RIIβ) and three isoforms of the catalytic subunit (Cα, Cβ, and Cγ), while the total 
number of GPCRs in the human genome has recently been estimated at over 
800 receptors (11). Several years after the compartmentation hypothesis was 
suggested, a previously unknown protein was identified by Sarkar et al as a 
contaminant that co-purified with RII following cAMP-sepharose affinity 
chromatography (12). This protein, now known as an A-kinase anchoring protein 
(AKAP), provided the molecular mechanism for cAMP-PKA signal 
compartmentation (13). 
 AKAPs are a diverse family of proteins that share little sequence 
homology and are defined only by their ability to bind PKA. The total number of 
AKAPs is estimated to be >70, resulting from alternative splicing of mRNAs 
encoded by 43 different genes (14). While the majority of AKAPs interact only 
with RII, a few dual specificity AKAPs have been identified that bind both RI and 
RII, though the affinity for RI is typically several fold less (15, 16). AKAPs interact 
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with the N-terminal dimerization/docking domain of the R subunit dimer through a 
14-18 amino acid amphipathic helix sequence (17). By simultaneously binding to 
both PKA and a given substrate, AKAPs direct PKA phosphorylation to a specific 
substrate or set of substrates (Fig 1.1).   
The functional significance of AKAPs has been well established by 
disrupting AKAP-PKA binding (18).  Disruption of PKA anchoring by AKAP is 
most commonly achieved using Ht31(493-515) peptide, a fragment of an AKAP 
cloned from human thyroid. This fragment represents the minimum necessary 
region for PKA binding to the AKAP and is generally referred to simply as Ht31 
(19). In hippocampal neurons, Ht31 has been shown to uncouple PKA from a-
amino-3-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors, 
resulting in attenuated postsynaptic AMPA currents (20).  Disruption of PKA 
anchoring in the pancreatic β-cell line RINm5F has been demonstrated to block 
cAMP responsive insulin secretion and to suppress cAMP mediated intracellular 
calcium elevation (21). Similar disruption of normal function by interfering with 
PKA anchoring in sperm has been observed as well, with Ht31 inhibiting cAMP 
dependent motility in a time and concentration dependent manner (22). 
Additionally, it has been demonstrated that disrupting PKA anchoring in rat heart 
cells redistributes RII, with loss of the typical striated pattern.  Importantly, 
disruption reduces phosphorylation of several key PKA substrates including 
phospholamban (PLB), Ryanodine receptor (RyR), and Troponin I (TnI) after 
stimulation with isoproterenol, and also produces changes in cardiac contractile  
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Figure 1.1 AKAP compartmentalizes PKA signaling by anchoring PKA to specific substrates. 
PKA binds to AKAP through its regulatory subunit dimer (R), which associates with AKAP through 
the dimerization/docking domain. In the inactive conformation, the catalytic subunit (C) is bound 
to the complex via the inhibitory domain of the regulatory subunit. Activation of a GPCR leads to 
cAMP production by AC. The increase in cAMP causes local activation and release of the PKA 
catalytic subunit resulting in phosphorylation of the AKAP bound substrate, which in this example 
is a Na+ channel. The increase in cAMP is confined to the local area and returned to baseline via 
PDE. The diffusion of cAMP away from AC and its degradation by PDE is represented by the 
yellow gradient. 	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parameters (23, 24).  Together, these examples clearly show the importance of 
PKA anchoring for regulation of substrate phosphorylation, leading to changes in 
cellular physiology. 
The ability of AKAPs to focus the catalytic activity of PKA on a particular 
substrate results from simultaneously associating with both the kinase and 
substrate. This has been demonstrated using the uni-molecular Förster 
resonance energy transfer (FRET) sensor of PKA activity, A-kinase activity 
reporter 2 (AKAR2) (25). By modifying AKAR2 to include a C-terminal RII binding 
site, Dodge-Kafka et al were able to show that PKA anchoring to substrate 
(AKAR2) augmented both the speed and magnitude of the AKAR2 reporter 
response (26). Similar results have been obtained in a more physiologically 
relevant context by preventing the association of AKAP with a specific PKA 
substrate in cells. β-adrenergic stimulation of cardiac myocytes leads to 
phosphorylation of PLB, producing changes in Ca2+ handling and contractility. 
Disruption of the AKAP7δ-PLB interaction in rat heart cells using a competitive 
peptide inhibitor attenuated isoproterenol induced PLB phosphorylation by up to 
50% (27). 
Although the primary role of AKAPs is most often considered to be 
compartmentation of cAMP-PKA signaling, AKAPs are able to assemble 
multimolecular signaling complexes that can include almost any type of 
regulatory enzyme (14). The ability of AKAPs to act as scaffolds for enzymes 
other than PKA was first discovered in 1995 by Coghlan et al (28). This work 
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demonstrated that AKAP79 interacts with and inhibits the actions of protein 
phosphatase 2B (PP2B). A ternary complex of PKA, AKAP, and PP2B was 
isolated from bovine brain, and colocalization of these components was 
established in cultured hippocampal neurites. This result suggests that AKAPs 
could coordinate regulation of the phosphorylation state of neuronal substrates. 
As the diversity of regulatory enzymes found to interact with AKAPs has 
expanded, the idea of cAMP-PKA signal compartmentation has evolved 
accordingly. The ability of many AKAPs to form multi-molecular complexes 
including AC, PDE, PKA, and a specific PKA substrate allows AKAPs to 
coordinate a cAMP microdomain in which all components necessary for signaling 
are colocalized (29). Although numerous AKAPs are capable of coordinating 
signaling microdomains, the work presented within is focused upon AKAP7 
specifically. 
 
AKAP7 (AKAP18) 
 In 1997 Gray et al reported the discovery of a 15kD protein associated 
with the L-type Ca2+ channel (LTCC) that physically links PKA to the channel, 
thus facilitating regulation of voltage-dependent potentiation (30). Consistent with 
the current AKAP naming scheme, this protein was called AKAP15. Soon after, 
an 18kD AKAP was identified that similarly associated with the LTCC (31). While 
it was suggested that AKAP18 was likely a homologue of AKAP15, cloning of 
AKAP18 related cDNAs revealed that AKAP15 and AKAP18 were, in fact, the 
	   10 
same (32). Additional isoforms of AKAP18 that arise from the same gene 
(AKAP7) but are differentially localized were also discovered. AKAP15/18, now 
referred to as AKAP18α, is the shortest of the isoforms and is targeted to lateral 
plasma membrane by a C-terminal (residues 1-16) lipid modification region that is 
both myristoylated (G1) and palmitoylated (C4, C5) (31). AKAP18β, a slightly 
longer AKAP containing a 23 amino acid insertion between the C-terminal lipid 
modification region and the RII binding region, localizes to both lateral and apical 
plasma membrane. AKAP18γ, a larger 37kD isoform lacking the lipid modification 
sites, localizes both to cytosol and to plasma membrane via direct protein-protein 
association. AKAP18δ, the largest of the AKAP18 isoforms, is highly similar to 
AKAP18γ in both structure and localization with an additional 27 amino acid 
segment at the N-terminus (Fig 1.2) (33). 
 The most well studied isoform of AKAP18 is AKAP18α, which functions 
primarily to regulate PKA phosphorylation of various ion channels including the 
LTCC (30, 31, 34), the K+ channel complex KvLQT1/Isk (35), and voltage-
sensitive Na+ channels (VSNC) (36-38). Association of AKAP18α with LTCCs 
and VSNCs requires both lipid modification of the N-terminus and direct binding 
to the channel through a leucine zipper motif positioned distal to the RII binding 
site (amino acids 42-49) (31, 34, 38, 39).  Functionally, AKAP18α has been 
demonstrated necessary for PKA dependent modulation of current through all of 
the channels mentioned above. Disruption of AKAP18α membrane targeting has  
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Figure 1.2 AKAP18 isoforms. A) Structure of each of the isoforms. AKAP18α and AKAP18β 
represent the short isoforms, which contain a membrane targeting sequence. The genes for the 
short isoforms are identical with the exception of an insertion in AKAP18β (orange region). 
AKAP18γ and AKAP18δ represent the long isoforms of AKAP18 and do not contain a membrane-
targeting region although they do both associate with membranes via protein-protein interaction. 
These isoforms are identical except for the first 27 amino acids of AKAP18δ. B) Cellular location 
and known substrates of each AKAP18 isoform. 
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been shown to reduce Ca2+ current and to blunt GLP-1 mediated insulin secretion 
in RINm5F pancreatic β-cells (31). In the heart, AKAP18α anchoring of PKA to 
the CaV1.2 channel was found necessary for β-adrenergic regulation of cardiac 
contraction with similar reductions in Ca2+ current produced upon disruption of 
AKAP18α-Cav1.2 binding (39). Permanent disruption of this interaction in mice, 
by knocking out the C-terminal region of the Cav1.2 channel (LTCC), leads to the 
development of heart failure (40). The KVLQT1/Isk complex, a component of the 
delayed rectifier K+ current that functions to repolarize cardiac myocytes, is also 
regulated by AKAP18α. Phosphorylation of KVLQT1 has been shown to increase 
current amplitude, increase the characteristic deactivation time of the channel, 
and to negatively shift its activation curve (35). In neuronal cells, dopamine 
stimulated PKA phosphorylation of NaV1.2 channels reduces peak Na+ current 
by 20-50% (41). Disruption of AKAP18a interaction with Nav1.2 channels with a 
competitive inhibitory peptide resulted in a 20% reduction in dopamine induced 
peak Na+ currents (38).  
 In comparison to AKAP18α, relatively little is known about the β, δ, and γ 
isoforms of AKAP18. Since it’s discovery in 1999 by Trotter et al, nothing has 
been published on AKAP18β. The longest isoform of AKAP7, AKAP18δ, was 
discovered in 2001 by Klussman and Rosenthal (42). In the kidney, activation of 
the vasopressin V2 receptor on the basolateral surface of principal cells in the 
collecting duct leads to translocation of aquaporin 2 (AQP2) to the apical 
membrane surface, thus facilitating water reabsorption. Translocation of AQP2 
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containing vesicles to the apical surface is a PKA dependent process, which 
AKAP18δ was demonstrated to regulate (42). Interestingly, while AKAP18δ has 
been shown to translocate with AQP2 to the apical surface of principal cells, it 
appears that RII dissociates following cAMP stimulation and does not translocate 
with AKAP18δ to the apical surface (33). In the mouse heart, AKAP18δ localizes 
PKA to the phospholamban (PLB)-sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPase (SERCA) complex at the sarcoplasmic reticulum (SR) via direct 
interaction of AKAP18δ with PLB (27). The interaction of PLB with SERCA 
prevents translocation of Ca2+ from the cytosol into the SR (43). Phosphorylation 
of PLB at S16 by PKA dissociates PLB from SERCA, thereby restoring its activity. 
Disruption of AKAP18δ-PLB binding with Ht31 significantly diminished PLB 
phosphorylation, demonstrating that AKAP18δ is necessary for PLB 
phosphorylation (27). It is important to note that AKAP18γ replaces AKAP18δ in 
human myocytes, so one may consider AKAP18γ homologous to AKAP18δ in the 
regulation of PLB (44). Like AKAP18β, AKAP18γ was identified by Trotter et al in 
1999 as a novel long isoform of AKAP18 (32). AKAP18γ was shown to partition 
equally between cytosolic and particulate fractions and was hypothesized to 
associate with membranes via direct protein-protein interaction due to the lack of 
a lipid anchor. While AKAP18γ contains a consensus nuclear localization 
sequence, the scaffold is not consistently localized to nuclei. The initial 
description of AKAP18γ localization did not note its presence in nuclei, though it 
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was later described as localizing RI to the nuclear membrane in mouse 
oocytes(45).  
 Similar to other AKAPs, AKAP18 is capable of binding enzymes other than 
PKA, which may serve regulatory functions within the AKAP complex. Co-
expression of the epithelial Na+ channel (ENaC) and AKAP18α has been 
demonstrated to reduce Na+ conductance by 80-90%, however the reduction in 
channel activity was found to be unaffected by either PKA activation or inhibition 
(46). Reduced ENaC activity was instead determined to result from the activity of 
PKCa, which was shown to interact with AKAP18α. This interaction has been 
shown not only for AKAP18α, but also for AKAP18γ (47). Scaffolding of PKCα by 
AKAP18 has been demonstrated to increase the activity of PKC, amplifying both 
the rate and magnitude of phosphorylation while also insulating PKC from the 
effects of inhibitors (48). AKAP18γ has also been shown to interact with protein 
phosphatase 1 (PP1) as well as its inhibitor I-1 (49). Phosphorylation of I-1 by 
AKAP18γ-linked PKA is known to result in inhibition of PP1 activity and is 
suggested to act as a feed-forward mechanism that would potentiate 
phosphorylation of AKAP18γ bound PKA substrates like PLB. 
 
Coordination of PKA phosphorylation by AKAPs 
 The functional and physiological consequences of PKA scaffolding by 
AKAPs are well known. This class of proteins not only functions to 
compartmentalize signaling by directing PKA phosphorylation to a particular 
	   15 
substrate, it also augments PKA kinetics, increasing both the rate and magnitude 
of phosphorylation (26). However, precisely how AKAPs confer specificity to the 
actions of PKA remains unclear. The established mechanism of PKA activation 
appears to necessitate the release of the catalytic from its regulatory subunit, 
effectively negating the tethering actions of AKAP (10).  The most commonly 
cited hypothesis is that AKAPs act to increase the local concentration of PKA, 
thus upon activation a large pool of active PKA is available to phosphorylate 
substrate. This hypothesis is unsatisfying given that the local concentration of 
PKA will quickly diminish with the rapid diffusion of PKA away from its point of 
release. 
 Much of the accumulated evidence suggesting that the catalytic subunit 
must be released from its regulatory subunit to phosphorylate substrate comes 
from in vitro experiments. The possibility that PKA is not released in vivo remains, 
and there has been some evidence to suggest that this is the case. In a series of 
fluorescence anisotropy experiments with PKA containing a fluorescently labeled 
catalytic subunit, Yang et al demonstrated that fluorescence anisotropy did not 
increase upon addition of cAMP as was expected, suggesting that the catalytic 
subunit was not released (50). They also showed that the un-dissociated 
complex retained full catalytic activity. According to Martin et al, the release of the 
catalytic subunit is dependent upon auto-phosphorylation of the regulatory 
subunit (51). Cell expressing PKA with mutant RII subunits that are unable to be 
autophosphorylated do not release the catalytic subunit in response to cAMP 
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stimulation. More recently, Smith et al were able to demonstrate that the catalytic 
subunit of PKA is retained within the AKAP complex following stimulation of PKA 
activity(52). 
 The work presented here focuses upon the regulation of PKA 
phosphorylation by AKAP18γ. In chapter 2, I present evidence of AKAP7γ 
dimerization and show via computational modeling how dimerization could 
potentially increase the magnitude of substrate phosphorylation. In chapter 3, I 
demonstrate that the interaction of AKAP7γ with PLB is dependent on the 
phosphorylation state of PLB, and show that this state-dependent interaction may 
allow small quantities of AKAP18γ to coordinate phosphorylation of large 
quantities of PLB. Finally, in chapter 4, I demonstrate via Langevin Dynamic 
simulation of the AKAP-PKA complex that the length and flexibility of the 
unstructured tether region of the regulatory subunit potentially modulates the 
catalytic rate of PKA. I further demonstrate by modeling that release of the 
catalytic subunit from the complex does not result in efficient phosphorylation of 
AKAP bound substrate, suggesting that the increased local concentration 
hypothesis for compartmentation by AKAPs is incorrect.  Instead, my work 
suggests that AKAPs work by affecting the efficiency of phosphorylation 
reactions. In sum, the work presented here changes our model of AKAP signaling, 
demonstrating a new mechanism of PKA regulation by the AKAP7γ complex.  
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AKAP7γ  Oligomerization augments PKA signaling  
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Abstract 
 
A-kinase anchoring proteins constitute a family of scaffolding proteins that 
contribute to spatiotemporal regulation of phosphorylation events mediated by 
cAMP-dependent protein kinase A (PKA).  In particular, AKAP7 is a family of 
alternatively spliced proteins that participates in cardiac calcium dynamics.  Here, 
we demonstrate via pull-down from transfected HEK-293 cells and by direct 
protein-protein association that AKAP7γ self-associates.  Self-association 
appears to be an isoform specific phenomenon, as AKAP7α did not associate 
with itself or with AKAP7γ. Surface plasmon resonance suggests that the 
AKAP7γ self-association occurs via two high affinity binding sites with KD values 
in the low nanomolar range. Mapping of the binding sites by peptide array reveals 
that AKAP7γ interacts with itself through two regions of the protein. Photon 
counting histogram analysis (PCH) of AKAP7γ-EGFP expressed in HEK-293 
cells confirmed that AKAP7γ-EGFP self-associates in the cell as well. Lastly, 
computational modeling of PKA dynamics within AKAP7γ complexes suggests 
that oligomerization may augment phosphorylation of scaffolded PKA substrates.  
In conclusion, our study reveals AKAP7γ self-associates to form a homo-dimer 
and possibly higher-order oligomers and that this phenomenon could be an 
important step in mediating effective substrate phosphorylation in cellular 
microdomains. 
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Introduction 
 Phosphorylation of target proteins is a key mechanism utilized by the cell 
to induce changes in physiology and function. Numerous kinase-substrate 
interactions have been defined, yet the mechanism through which specificity of 
these phosphorylation events is achieved is still unclear.  Recent work has 
suggested that the subcellular localization of signaling enzymes to discrete 
locations in the cell confers spatiotemporal control over phosphorylation events 
(53).  This is facilitated by scaffolding proteins, which tether the kinase to the 
same signaling complex as its substrates, allowing for increased speed and 
amplification of phosphorylation events (54). While the physiological significance 
of many kinase-binding scaffolds has been investigated, the influence of the 
molecular architecture of the complex on cellular processes is presently unclear. 
 Oligomerization of signaling enzymes is an important mechanism for the 
transduction of cellular signals (55, 56). Whether forming a hetero or homo 
oligomer, this process often begins at the level of the receptor as a first step in 
transducing a signal from outside the cell to the intracellular environment (57). 
Oligomer formation is not limited to upstream signaling events. A few recent 
studies have demonstrated that scaffolding proteins can oligomerize, influencing 
their signaling functions.  For example, the yeast scaffold Ste5, which initiates the 
mitogen-activated protein (MAP) kinase cascade in the Saccharomyces 
cerevisiae pheromone response pathway, dimerizes upon pheromone treatment, 
to enhance MAP kinase signaling in the cell (58). Similarly, oligomerization of β-
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arrestin1 sequesters the scaffold in the cytoplasm, inhibiting its nuclear actions 
(59). Importantly, these examples demonstrate that oligomerization greatly 
impacts the function of the scaffold. 
 For cAMP signaling, A-kinase anchoring proteins (AKAPs) focus the 
actions of the cAMP-dependent protein kinase (PKA) to specific targets, allowing 
for microdomains of kinase activity (54). It is becoming evident that AKAPs have 
a more profound effect on the regulation of substrate phosphorylation than simply 
binding PKA. Many AKAPs have been shown to bind to phosphodiesterases, 
protein phosphatases, and adenylyl cyclases as well, allowing for localized 
control of cAMP concentration (60-62). Thus, AKAPs are able to coordinate all 
components necessary for PKA signaling, lending support to the concept of 
holistic substrate phosphorylation regulation by AKAPs. 
 Our recent investigations focused on defining AKAP7-orchestrated cAMP 
microdomains.   AKAP7 is a family of alternatively spliced isoforms that are 
known to play a role in cardiac calcium dynamics (27, 63).  Here, we reveal that 
AKAP7γ oligomerizes, as demonstrated both in vitro and in a cellular context, and 
we predict via computational modeling that this may result in enhancement of 
PKA substrate phosphorylation. This self-interaction is limited to the large 
isoforms of AKAP7, correlating with previous findings that AKAP7α and AKAP7γ 
are differentially targeted in the cell and display unique functions (32).  Using 
peptide array to define the sites on AKAP7γ that mediate binding found several 
domains involved in the oligomerization.  In agreement with this finding, surface 
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plasmon resonance analysis confirms that AKAP7γ interacts with itself via 
several high-affinity binding sites.  Using photon counting histogram (PCH) 
analysis we are able to detect dimerization of AKAP7γ in live cells.  In order to 
investigate the functional significance of oligomerization on substrate 
phosphorylation, we developed a mathematical model using the Virtual Cell 
Software (http://www.vcell.org).  Computational analysis suggests that formation 
of dimeric complexes enhances the magnitude of substrate phosphorylation. 
Collectively, our work demonstrates that oligomerization of AKAP7γ impacts 
phosphorylation events orchestrated by the AKAP and suggests that these 
findings may be applied to other AKAP complexes. 
 
Materials and Methods 
Antibodies 
For western blot analyses, the following antibodies were used: mouse 
monoclonal anti-GFP (Santa Cruz, 1:1000), goat polyclonal anti-dsRED (Santa 
Cruz, 1:1000), rabbit anti-His tag (Millipore, 1:10,000), rabbit anti-mCherry 
(BioVision, 1:5000) and mouse anti-GST tag (Santa Cruz, 1:10,000).  To 
immunoprecipitate EGFP-tagged proteins, rabbit anti-GFP (Santa Cruz 3 µg) was 
used. 
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Construct design   
AKAP7γ-pET32a, AKAP7α-EGFP-N1 and AKAP7γ-EGFP-N1 were used as 
previously described (31, 32, 49). AKAP7γ 1-150-EGFP and AKAP7γ 150-end-
EGFP were constructed by PCR amplification and sub-cloning into the EcoRI-
BamHI sites of pEGFP-N1 (Clontech). AKAP7γ-pMAL was constructed by PCR 
amplification and sub-cloning into the BamHI-EcoRI sites of pMal-c5E (NEB).  
AKAP7γ-mCherry was constructed by PCR amplification and sub-cloning into the 
EcoRI-BamHI sites of pmCherry-C1 (Clontech). Monomeric EGFP and tandem 
EGFP used for PCH analysis were obtained from the lab of Dr. Kathy Herrick-
Davis. 
 
Recombinant Protein Purification   
For purification of recombinant AKAP7γ-His/S-tag, bacteria were grown to OD595 
0.8 then induced with IPTG (1mM final concentration) for 3hrs. After 
centrifugation, the bacteria were lysed in binding buffer (20mM HEPES (pH 7.4), 
0.5M NaCl, 5mM imidazole along with 0.5% triton-X, 0.25mg/ml lysozyme, 1mM 
DTT, 1mM EDTA, and Protease Inhibitor Cocktail) for 2hrs. Following 
centrifugation, protein was purified from supernatant by Ni-NTA agarose 
pulldown overnight (0.5mL of 50% slurry; Ni-NTA solution, Qiagen). Ni-NTA 
agarose was washed 3x in binding buffer and protein was eluted with binding 
buffer + 800mM imidizole. Protein was concentrated with Amicon Ultra centrifugal 
filters (Millipore). Elution buffer was slowly exchanged with PBS while 
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concentrating the protein in the centrifugal tubes. Protein concentration was 
determined by comparison to BSA standards via image densitometry of 
coomassie stained SDS-PAGE gels. Image densitometry was performed with 
Image J software (NIH).  
 A similar protocol was followed for AKAP7γ-maltose binding protein (MBP) 
purification.  The MBP tagged protein was lysed in buffer containing protease 
inhibitor cocktail (20mM Tris-HCl (pH 7.4), 200mM NaCl, 1mM each of EDTA, Na 
Azide, and DTT). Separated cell lysate was passed through amylose resin 
packed column, followed by 5 washes with lysis buffer. The protein was eluted 
with lysis buffer containing 10mM maltose.  The protein was concentrated and 
analyzed as described above.  
 
Cell transfection 
For analysis of AKAP7γ binding to itself, HEK-293 cells at 50% confluency 
were transfected using calcium phosphate precipitation with pEGFP-AKAP7γ and 
either mCherry-AKAP7γ or mCherry control (10µg) overnight under 5% CO2 at 
37°C.  Cells were harvested 18hrs later for cell extract. 
 For PCH, HEK-293 cells were grown on uncoated glass coverslips to 70% 
confluency and transfected with 300ng plasmid DNA (EGFP, tandem EGFP or 
AKAP7γ-EGFP) in Opti-MEM (Invitrogen) serum free medium using 6µl PLUS 
reagent and 4µl lipofectamine. After 2hrs, transfection media was replaced with 
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serum supplemented DMEM (10%FBS). Cells were used for photon counting 
histogram analysis 12-24hrs post-transfection. 
 
Pull-down Assays 
In-vitro: Purified His/S tagged AKAP7γ (5µg) was incubated with either AKAP7γ-
MBP (5µg) or MBP (5µg), and rocked overnight at 4°C. The next day, the 
amylose resin was added for 4hrs to isolate the complex.  The amylose beads 
were washed 4x in lysis buffer (as described in maltose tagged protein 
purification above) for 10-15min while rocking.  The components of the complex 
were then separated via SDS-PAGE and analyzed by western blot. 
 
From cell supernatant:  Lysates prepared from AKAP7γ-EGFP transfected HEK-
293 cells were incubated with either 5µg purified recombinant AKAP7α-His/S-tag 
pre-loaded on S-agarose beads (Novagen), or with purified 5µg AKAP7γ-MBP 
pre-loaded on amylose agarose beads (Novagen).  For control groups, either 
unrelated His/S-tag protein or isolated MBP was used.  The pull-downs were 
rocked overnight at 4°C, followed by 4 washes with their respective buffers for 
10-15min while rocking. The isolated complex was then subjected to separation 
via SDS-PAGE followed by western blot analysis. 
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SPR Analysis 
SPR analysis was performed using the BIAcore T100 platform. Purified 
recombinant AKAP7γ or AKAP7α were covalently immobilized to the surface of a 
sensor chip (BIAcore type CM5) using NHS (N-hydroxysuccinamide) and EDC 
[1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide] (Biacore amine coupling kit).  
The amount of ligand bound was 150RU (resonance units).  Protein analytes 
(AKAP7γ or AKAP7α) were diluted over a range of concentrations (12.5-200nM) 
in HBS buffer (10mM Hepes (pH 7.4), 150mM NaCl and 0.005% Surfactant P20) 
and were injected over the sensor surface at a flow rate of 30µl/min for 300s.  
Post injection phase, dissociation was monitored in HBS buffer for 300s at the 
same flow rate.  The surface was regenerated between injections using 10mM 
NaCl at a flow rate of 50µl/min for 30s.  Sensorgrams were analyzed by BIAcore 
T100 evaluation software using the appropriate biophysical models. 
 
Peptide array membrane synthesis and S-tagged AKAP7γ overlay 
Human AKAP7γ peptides were synthesized as 20-mer peptides with three amino 
acid offsets on membranes using a Multipep automated peptide synthesizer 
(INTAVIS Bioanalytical Instruments AG, Koeln, Germany).  The peptide array 
membranes were blocked for 2 hours in 1% casein in TBST (tris-buffered saline 
with 1% tween) before incubation with 2 µg/ml recombinant human S-tagged 
AKAP7γ in 1% casein (in TBST) overnight at 4°C. Thereafter the membranes 
were washed five times in TBST for 5 min before incubation with HRP-conjugated 
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anti-S tag antibody (Abcam, ab18589, 1:2500) for 1 hour at room temperature. 
Binding was detected using ECL Prime (RPN 2232, GE HealthCare) and 
chemiluminescence signals were detected by Las 1000 (Fujifilm, Tokyo, Japan).  
 
Photon Counting Histogram Analysis 
Photon counting in live HEK-293 cells was performed with a Zeiss LSM 510 
ConFocor3 confocal microscope mounted on an AxioVert 200M. Excitation was 
achieved at 488nm with a 30mW Argon laser at 50% power with attenuation set 
to 0.5. Fluorescence emission was collected with a 40X 1.2NA water immersion 
objective (Zeiss C-Apochromat 1.2W Korr UV-Vis-IR). Detection was performed 
with an avalanche photodiode (Zeiss). For each cell, five 10s measurements 
were made from five different locations within a given cell. Photon-counting 
histograms (PCH) were generated using LSM-FCS software with a bin time of 
10µs. Global analysis of measurements with count rates ranging from 20-100 
kHz was performed for each construct. Monomeric and dimeric (tandem) EGFP 
histograms were fit using a single component model, while AKAP7γ-EGFP 
histograms were fit using a two-component model with the brightness values 
constrained to those derived from the fit of the monomeric and dimeric EGFP.  
Measurements exhibiting photo-bleaching or other anomalies producing 
instability of the fluctuation trace were excluded from analysis. A single-photon 
three-dimensional Gaussian model was assumed for the excitation volume. 
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Computational Modeling 
A compartmental deterministic model of scaffold oligomerization was 
implemented using the Virtual Cell modeling software (http://www.vcell.org). The 
model is composed of 18 species, three compartments (plasma membrane, 
cytosol, and endoplasmic reticular membrane), and 11 reactions. The reaction 
network can be considered as being composed of four general modules: 1) 
production and degradation of cAMP, 2) the dynamic interactions of regulatory 
subunit, catalytic subunit and cAMP in the cytosol, 3) the dynamics of these 
same proteins and cAMP scaffolded on the ER membrane by AKAP, and 4) 
phosphorylation/dephosphorylation of target protein X on the ER membrane. A 
diagram of the reaction network and table of the kinetic parameters is shown in 
figure 1. For each oligomeric state of the scaffold represented in the different 
versions of the model, the concentration of each species is initialized with a value 
near steady state in unstimulated conditions. Each simulation is allowed to run for 
200s allowing each species to reach its equilibrium constant for each oligomer 
before stimulation. Stimulation of PKA activity is achieved by increasing the 
amount of AC present on the plasma membrane from 5/µm2 to 50/µm2 for a 
period of 100s, simulating the increase in Gs-associated AC during β-adrenergic 
stimulation. The resulting increase in cAMP leads to activation of scaffolded PKA 
and phosphorylation of the target protein X. Active PKA is then inactivated by 
interacting with PKI. The ability of PKA to self-regulate via autophosphorylation 
has been shown previously (51). We hypothesized that if a single catalytic 
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subunit were to be activated within an AKAP complex, this may subsequently 
lead to activation of the remaining population of PKA within the complex. This 
hypothesis was implemented via the following equation (eq. 1). This equation 
adjusts for the probability of all catalytic subunits within the oligomeric complex 
becoming active following activation of a single catalytic subunit in the complex, 
where n represents the oligomeric state of the scaffold (ex. 1 = monomer, 2 = 
dimer): 
(1)  𝑇𝑜𝑡𝑎𝑙  𝐴𝐾𝐴𝑃  𝑏𝑜𝑢𝑛𝑑  𝑃𝐾𝐴 1− !"#$%&'(!"#$% ! ∗ 𝑛 
The result of eq. 1 represents the amount of catalytic subunit available to 
phosphorylate its target, X, and is substituted for [E] in the Henri-Michaelis 
Menten irreversible reaction step for phosphorylation of X (eq 2). 
(2) 𝑉 = ! ∙!!"#∙[!]!!![!]  
Simulations of all oligomeric states have the same amount of active AKAP-
scaffolded PKA both at equilibrium and during stimulation. The behavior of the 
AKAP-scaffolded PKA is altered by eq. 1&2 to reflect the hypothesized behavior 
in each oligomeric state.  
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Figure 2.1 Computational Model of AKAP oligomerization A) Network diagram B) Reaction 
kinetic parameters 	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Results 
Direct cellular association of AKAP7γ with itself 
 In order to understand the molecular architecture of the AKAP7γ signaling 
complex and to determine if the AKAP can be the basis for higher order 
structures, we first looked to see if purified, recombinant AKAP7γ could pulldown 
an AKAP7γ complex when transiently expressed in cells. Lysate prepared from 
HEK-293 cells transfected with AKAP7γ-EGFP was incubated with amylose 
beads charged with either AKAP7γ-maltose binding protein (MBP) or MBP alone. 
The protein stain of the nitrocellulose before western blot analysis showing 
AKAP7γ-MBP (lanes 1 and 2) or MBP alone (lanes 3 and 4) is shown in Figure 
2.2A, lower panel.  Input lysate (20µl) from cells expressing AKAP7γ-EGFP is 
shown in lane 5.  Importantly, AKAP7γ-MBP was able to pulldown AKAP7γ-EGFP 
from the transfected cell lysate (Figure 2.2A, upper panel, lanes 1 and 2), 
suggesting the AKAP7γ signaling complex may contain multiple AKAP7γ 
molecules. As a control, beads charged with purified MBP alone did not pulldown 
AKAP7γ-EGFP (Figure 2.2A, upper panel, lanes 3 and 4). To verify the existence 
of such complexes in cells, we co-expressed AKAP7γ-mCherry with either 
AKAP7γ-EGFP or EGFP alone in HEK-293 cells.  AKAP7γ-mCherry input (20 µL) 
for each immunoprecipitation is shown in Figure 2.2B, lower panel.  
Immunoprecipitates from these cells isolated with an anti-GFP antibody 
demonstrate that AKAP7γ-mCherry and AKAP7γ-EGFP associate in cells (Figure 
2.2B, upper panel, lanes 3 and 4), while EGFP control does not co-precipitate  
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Figure 2.2 Direct cellular association of AKAP7γ with itself.  
A) Lysates from AKAP7γ-EGFP transfected HEK-293 cells were subjected to pulldown assays 
using bacterially purified AKAP7γ-MBP (maltose binding protein) pre-charged on amylose 
agarose resin (lanes 1 and 2) or Maltose pre-charged on amylose agarose resin (lanes 3 and 4). 
Input from the transfected cells (20µl) is shown in lane 5. Anti-GFP antibody was used for 
detecting protein interactions by Western blot analysis (upper panel) while the protein stain of the 
nitrocellulose before western blot analysis is shown in the lower panel. n=3. B) Western blot 
analysis of anti-GFP immunoprecipitates isolated from HEK-293 cells co-transfected with 
AKAP7γ-mCherry and either EGFP alone, or AKAP7γ-EGFP (upper panel). To confirm 
immunoprecipitation of both EGFP and AKAP7γ-EGFP, the nitrocellulose membranes were 
stripped and reprobed for GFP using a monoclonal anti-GFP antibody (middle panel).  Lower 
panel depicts mCherry western blot analysis of the input from each condition. n=3. C) In vitro 
pulldown of purified S-tagged AKAP7γ incubated with AKAP7γ-MBP precharged on amylose 
agarose resin (lanes 1 and 2) or control MBP (lane 3).  Anti-His antibody was used to detect the 
interaction (upper panel). Equal amounts of S-tagged AKAP7γ were used in each condition, as 
shown by analysis of the input used in each experiment (middle panel).  Lower panel shows the 
protein stain of the nitrocellulose before western blot analysis to demonstrate equal amounts of 
MBP-tagged proteins. n=3. 
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AKAP7γ-mCherry (lanes 1 and 2).  As a control, both the EGFP (lanes 1 and 2) 
and AKAP7γ-EGFP (lanes 3 and 4) immunoprecipitates were probed with anti-
GFP to demonstrate the immunoprecipitation of both proteins (Figure 2.2B, 
middle panel). This co-precipitation could be due to multiple binding sites on 
other common binding partners within the AKAP complex.  To determine if 
AKAP7γ can directly associate with itself, we conducted a pulldown assay using 
amylose beads charged with either bacterially expressed AKAP7γ-MBP (lanes 1 
and 2) or MBP alone (lane 3) incubated with bacterially expressed S-tagged 
AKAP7γ. The protein stain of the nitrocellulose membrane before western blot 
analysis displaying the MPB tagged proteins used is shown in Figure 2.2C, lower 
panel. S-tagged AKAP7γ  input for each experiment is shown in the middle panel. 
Importantly, we detect a direct association between S-tagged AKAP7γ and 
AKAP7γ-MBP (lanes 1 and 2, upper panel), but not S-tagged AKAP7γ and MBP 
(lane 3, upper panel).  Based on these experiments, we conclude AKAP7γ can 
stably associate with itself.   
 
Isoform specificity and binding affinity of AKAP7γ oligomers  
 The AKAP7 gene encodes at least 4 alternatively spliced isoforms: α, β, γ, 
and δ (32). The smaller isoforms (α & β) are lipid modified in their N-terminal 
domain, directing their location to the plasma membrane (31). However, the 
larger isoforms (γ & δ) require additional protein-protein interactions for their 
intracellular targeting (32).  We investigated whether the shorter isoforms could 
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also associate with themselves or other isoforms. To address this question, 
lysate was prepared from HEK-293 cells transfected with AKAP7γ-EGFP and 
incubated with purified recombinant S-tagged AKAP7α or AKAP7γ bound to S-
protein beads.  The protein stain of the nitrocellulose before western blot analysis 
demonstrating the beads are charged with AKAP7α (lanes 2 and 3) or AKAPγ 
(lanes 4 and 5) is shown in Figure 2.3A, lower panel.  Input lysate (20 µl) from 
cells expressing AKAP7γ-EGFP is shown in lane 1.  Importantly, S-tagged 
AKAP7γ was able to pulldown AKAP7γ-EGFP specifically from the transfected 
cell lysate (Figure 2.3A, upper panel, lanes 4 and 5). However, we did not detect 
the presence of AKAP7γ-EGFP with AKAP7α pulldowns (Figure 2.3A, upper 
panel, lanes 2 and 3), suggesting there is no cross isoform interaction. To further 
confirm this observation, we conducted the inverse experiment. Lysate collected 
from HEK-293 cells transfected with AKAP7α-EGFP was incubated with S-beads 
charged with S-tagged AKAP7α (lanes 2 and 3) or AKAP7γ (lanes 4 and 5). As 
expected, we did not detect any interaction between the two isoforms (Figure 
2.3B, upper panel).   
 To further increase our understanding of this interaction, the detailed 
binding kinetics of the AKAP7γ interaction were analyzed by surface plasmon 
resonance (SPR).  AKAP7γ and AKAP7α were chemically conjugated to 
separate flow chambers of a CM5 sensor chip.  A range of concentrations of 
either AKAP7γ (black) or AKAP7α (red) (25nM to 200nM) was injected, and the  
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Figure 2.3 AKAP7γ forms homo-oligomers displaying high affinity interactions.  
A) Lysates from AKAP7γ-EGFP transfected HEK-293 cells were subjected to pulldown assays 
using bacterially purified S-tagged AKAP7α (lanes 2 and 3) or AKAP7γ (lanes 4 and 5) 
precharged on S-protein resin. Anti-GFP antibody was used for detecting protein interactions by 
western blot analysis (upper panel). Protein stain of the nitrocellulose membrane before western 
blot analysis is shown in the lower panel. Input from the transfected cells (20µl) is shown in lane 1. 
n=3. B) Lysates from AKAP7α-EGFP transfected HEK-293 cells were subjected to pulldown 
assays using bacterially purified S-tagged AKAP7α (lanes 2 and 3) or AKAP7γ (lanes 4 and 5) 
precharged on S-protein resin. Anti-GFP antibody was used for detecting protein interactions by 
western blot analysis (upper panel). Protein stain of the nitrocellulose membrane before western 
blot analysis is shown in the lower panel. Input from the transfected cells (20µl) is shown in lane 1.  
n=3. C) SPR was performed by immobilizing 150RU of AKAP7γ (black) and AKAP7α (red) in 
separate flow cells on a CM-5 chip and measuring the response when passing over a range of 
concentrations (25-200nM) of either AKAP7α (D) or AKAP7γ (C). The sensorgram was best fit 
with a heterogeneous ligand model suggesting the presence of two binding sites on AKAP7γ. The 
affinities of the two binding sites were 0.537nM and 79.7nM (χ2 = 1.33), as determined by the 
BIAcore T100 evaluation software.   
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binding dissociation constant (KD) was determined from the fit of the 
sensorgrams.  We detected a high affinity interaction between AKAP7γ and itself 
that is best fit with a heterogeneous ligand model, suggesting at least two sites of 
interaction that display binding affinities of 0.537nM and 79.7nM (χ2 = 1.33) (Fig. 
2.3C).  However, no significant binding between AKAP7α and AKAP7γ was 
detected.  This was confirmed in reciprocal experiments, where we chemically 
conjugated AKAP7α to the sensor. No binding between AKAP7α and AKAP7γ or 
itself was detected (Fig. 2.3D). These results support the hypothesis that AKAP7γ 
forms only homo-associations. 
 
Mapping the sites in AKAP7γ responsible for homo-association. 
 The SPR results suggest that multiple sites of interaction may exist 
between AKAP7γ and itself. To determine the number and location of binding 
sites, a series of AKAP7γ fragments were created (Figure 2.4A) and incubated 
with lysate from HEK-293 cells transfected with AKAP7γ-EGFP (Fig 2.4B). The 
protein stain of S-protein beads charged with the different AKAP7 proteins used 
in the experiment is shown in Figure 2.4A, lower panel.  Input lysate (20µl) from 
cells expressing AKAP7γ-EGFP is shown in the designated lane.   In confirmation 
of our previous results, recombinant purified full-length AKAP7γ, but not AKAP7α, 
was able to pulldown AKAP7γ-EGFP from transfected cell lysate (Figure 2.4B, 
upper panel).  Additionally, both halves of AKAP7γ, AKAP7γ(1-150) and 
AKAP7γ(150-323), were able to pulldown AKAP7γ-EGFP from transfected cell 
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lysate, revealing that each half of the protein participates in the homo-association 
of AKAP7γ (Fig 2.4A).  
To further refine the location of the binding sites, the human AKAP7γ 
sequence was synthesized as 20-mer peptides with three amino acid offsets on 
membranes using a Multipep automated peptide synthesizer, and then subjected 
to overlay with bacterially purified, full length, S-tagged AKAP7γ (Figure 2.4C, 
upper panel).  Using an HRP-conjugated anti-S tag antibody, binding was 
observed to two regions; amino acids 43-98 and amino acids 202-296. 
Importantly, the HRP-conjugated anti-S tag antibody did not detect any spots in 
the absence of overlay with purified AKAP7γ (Figure 2.4C, lower panel).  This 
data offers further confirmation that there are two regions of interaction between 
AKAP7γ and itself.  
 
Dimerization of AKAP7γ can be detected in cells 
 The existence of two sites of interaction of AKAP7γ with itself suggests the 
potential to form multimeric structures. This possibility was investigated via 
photon counting histogram (PCH) analysis of AKAP7γ-EGFP expressed in live 
HEK-293 cells. Photon counting histogram analysis is a method of fluorescence 
correlation spectroscopy that allows for determination of the size (brightness, ε) 
and concentration (number, n) of a given oligomer from fluctuations in signal 
intensity. This technique uses standard confocal optics to create a measurement 
volume on the order of 0.5fL. As fluorescent particles diffuse through the 
	   37 
	  
Figure 2.4 Mapping the sites in AKAP7γ responsible for oligomerization. A) Schematic depicting 
AKAP7γ fragments used for pulldown experiments. B) Lysates from AKAP7γ-EGFP transfected 
HEK-293 cells were subjected to pulldown assays using bacterially purified S-tagged 
AKAP7 deletion fragments precharged on S-protein resin; AKAP7γ-150-323, AKAP7γ-1-150, full-
length AKAP7γ or AKAP7α. Anti-GFP antibody was used for detecting protein interactions by 
western blot analysis (upper panel). Protein stain of the nitrocellulose membrane before western 
blot analysis is shown in the lower panel. Input from the transfected cells (20µl) is shown in the 
last lane. n=3. C) The full length AKAP7γ sequence was spotted as overlapping 20-mer peptides 
with 3 amino acid shifts on cellulose membranes and subjected to overlay using S-tagged 
AKAP7γ.  Binding was detected by chemiluminescence using an HRP-conjugated S-protein 
antibody (upper panel).  The antibody did not detect any binding in the absence of S-tagged 
AKAP7γ overlay (lower panel). n=4. 
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measurement volume, their signal is detected by a highly sensitive detector such 
as an avalanche photodiode. The change in signal intensity is dependent upon 
the average number of particles within the volume (n) and the brightness of a 
given particle (ε). At low average particle concentrations, the change in 
fluorescence intensity resulting from a single particle entering or leaving the 
volume is readily detected, while at high concentrations this change is less 
detectable. Detection of the change in intensity over time yields a fluctuation 
trace. The fluctuation trace (Figure 2.5A) is divided into small increments of time 
(bins) and the signal intensity (counts) is averaged within each increment. The 
average signal for each bin is then plotted as frequency vs. counts/bin to yield the 
photon counting histogram (Figure 2.5A), which can be fit to determine the 
brightness and concentration of the fluorescent particles present. Cells 
expressing low yet detectable amounts of AKAP7γ-EGFP were selected for 
analysis due to the dependence of signal variance on the inverse of the number 
of particles present in the confocal volume. For each cell chosen, five regions 
were selected from within the cytoplasm for analysis. Each region was measured 
5 times for 10s per measurement. The data for each construct was fit globally 
with either a single component model (EGFP monomer and dimer) or two 
component model (AKAP7γ-EGFP) yielding a brightness value (ε) and 
concentration for either one or two species respectively. This type of fitting allows 
for the derivation of a single brightness value based upon the aggregate data  
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Figure 2.5 Photon counting histogram detects dimerization of AKAP7γ in live cells. A) A 
representative section of the fluctuation trace (above). The fluctuation trace is divided into 10ms 
bins and plotted as a histogram of frequency vs. counts/bin (below). Fitting of the histogram yields 
the concentration (number, n) and brightness (e) of the fluorescent particles. B) Data summary. 
HEK-293 cells were transfected with monomeric EGFP, dimeric EGFP, or AKAP7γ-EGFP. 
Selected cells were measured 5 times at 5 different positions within the cytosol for 10s per 
measurement. Measurements exhibiting bleaching or other instabilities in fluorescence intensity 
were excluded from analysis. Global fitting of the data produced near ideal fits (χ2global of 1.0 is 
ideal). Monomeric and dimeric EGFP were fit using a single component model, while AKAP7γ 
was fit using a 2-component model allowing for the detection of both monomeric and dimeric 
AKAP7γ-EGFP. *Average concentrations and [Dimer]/[Total] were determined from the 52 
measurement in which the presence of dimer was detected. 
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from all measurements of a given fluorescent construct, rather than averaging 
individual values derived from each individual measurement. Global-fitting of the 
EGFP monomer and dimer yielded brightness values of 9468 ± 72 (χ2reduced = 
1.10) and 16967 ± 100 (χ2reduced = 1.14) respectively (Figure 2.5B). For AKAP7γ-
EGFP 75 total measurements from 5 cells were best fit using a two component 
model with brightness values constrained to 9500 and 17000 representing 
monomer and dimer respectively (χ2 = 1.04). Of 75 total measurements included 
in the analysis, dimer was detected in 52 measurements and in 42 
measurements >10% of the total particles detected represent dimer (Figure 2.4B). 
Among the 52 measurements that detect dimer, the average concentration of 
monomer is 19.81±2.40nM and the average concentration of dimer is 
3.99±0.06nM. On average, 20±0.3% of the particles detected is dimer, indicating 
that 28.7% of AKAP7γ-EGFP is in the dimeric form. Based upon the 
concentrations of monomer and dimer, the apparent Kd of dimerization falls in 
the range from 78.8-126nM with an average of 98.4nM. This apparent Kd is 
consistent with the kinetic data from SPR. Attempts to detect higher order 
oligomeric structures by fitting AKAP7γ-EGFP data with larger brightness values 
were unsuccessful. However, this does not exclude the possibility that higher 
order AKAP7γ oligomers exist. The concentrations of higher order oligomers was 
likely insufficient either for detection, or for discrimination from the population of 
monomers and dimers. This evidence offers further confirmation that self-
association of AKAP7γ occurs in live cells. 
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Oligomerization of AKAP7γ functions to increase target phosphorylation 
 Our finding that AKAP7γ is able to form homo-dimers is interesting and 
leads us to question the functional role of oligomerization. The two large regions 
of interaction make it exceedingly difficult to disrupt AKAP7γ oligomerization. 
Thus, we decided to test the possible functional significance of 
AKAP7γ oligomerization in silico. We created a compartmental deterministic 
model that simulates the dynamics of the PKA regulatory (RIIα) and catalytic 
subunits (Cα) in response to cAMP, both in the cytosol and on the endoplasmic 
reticulum (ER) membrane. We chose to model the dynamics of AKAP7γ at the 
ER due to recent work demonstrating localization of the scaffold at the ER in 
cardiac myocytes (27). Included in the model is autophosphorylation of RIIα, as 
this is documented as a key component for activation of Cα when complexed 
with RIIα (10, 51, 64). In our model, it is assumed that the probability of activation 
of all Cα subunits within an oligomer increases as the total number of activated 
Cα subunits increases (Equation 1, methods). Active Cα subunits were modeled 
to participate in the phosphorylation of a generic target protein X (X à pX) 
existing on the ER membrane (Equation 2, methods). The time course of 
formation of pX is shown for separate simulations that compare oligomeric states 
from monomer to tetramer (Figure 2.6A). Upon stimulation of PKA activity, the 
amount of pX increases in all cases. When the monomeric state (n=1) is 
simulated, phosphorylation of our target protein occurs as it would if the feed-
forward assumption is not made. Removal of the stimulus leads to  
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Figure 2.6  Oligomerization of AKAP7γ functions to increase target phosphorylation. A) Time 
course of target protein X phosphorylation for each oligomeric state. An increase in cAMP 
production is simulated from 0-100s resulting in activation of AKAP bound PKA and 
phosphorylation of target protein X. The inset shows the change in [pX] from baseline to maximal 
phosphorylation relative to the change in phosphorylation produced by the monomeric state. 
B) Time course of target X phosphorylation for a mixture of monomer and dimer as measured via 
PCH. The concentration of monomeric and dimeric AKAP complexes were adjusted so that 
71.3% of the total AKAP exists as monomer and 28.7% exists as dimer. An increase in cAMP 
production was simulated as above. The inset shows the change in [pX] from baseline to maximal 
phosphorylation relative to 100% monomer. 
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dephosphorylation of pX and return to baseline. Oligomerization of AKAP7γ 
affects the baseline, magnitude, and speed of phosphorylation of protein X (Fig. 
2.6A & 2.6B). The largest magnitude change of pX occurred in the dimeric state, 
with larger order AKAP7γ oligomers exhibiting decreased magnitude change in 
pX (Figure 2.6B). When the active scaffolded PKA population was adjusted to 
reflect a mixture of monomeric and dimeric states according to our PCH data, the 
baseline phosphorylation level remains low (8.26 molecules/µm2) while the 
magnitude change in pX increases by 76% in comparison to monomer only 
(Figure 2.6A & 2.6B). This analysis demonstrates the possible impact of AKAP7γ 
oligomerization on the rate of PKA substrate phosphorylation. 
 
Discussion  
 Significant work has demonstrated the impact of scaffolding on the 
organization of signaling proteins into discrete focal points of subcellular enzyme 
activity (65).  However, information regarding the molecular architecture of 
scaffolds and their influence on phosphorylation events is currently lacking.  Here, 
through the use of a combination of protein biochemistry, fluorescence 
correlation spectroscopy and computational modeling, we deciphered that the 
scaffolding protein AKAP7γ dimerizes in vitro and in cells. Our ability to detect 
dimerization via PCH indicates that dimerization is occurring in live cells.  
Importantly, computational modeling suggests that dimerization may act to 
increase target phosphorylation. These findings represent a previously 
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unappreciated mechanism involved in the configuration of AKAP complexes and 
the regulation of protein phosphorylation.   
 Oligomeric proteins, composed of two or more polypeptide chains, 
represent a major fraction of total cellular proteins (55). Interestingly, a search of 
the BRENDA enzyme database (http://www.brenda.uni-koeln.de/) reveals that of 
the total 452 human enzymes with known subunit composition, over 300 exist in 
multimeric states. Oligomerization of signaling proteins is a common 
phenomenon that occurs in many signal transduction networks. This is especially 
true at the level of the receptor, in which numerous examples of oligomerization 
exist (57, 66). Recent evidence suggests intracellular scaffolding proteins also 
oligomerize (67, 68). Several recent reports have demonstrated homo-
oligomerization of AKAP5, AKAP12 and AKAP-Lbc (69-71). Dimer formation of 
these AKAPs is mediated by direct protein-protein interactions. A leucine zipper 
motif in the N-terminus of AKAP-Lbc dictates the interaction while multiple 
domains of AKAP5 are required for dimerization (69, 71). As we have shown, 
AKAP7γ dimerization also occurs via direct interaction. Determination of the 
binding kinetics via SPR reveals that AKAP7γ forms a dimer via high-affinity 
interaction that occurs at two sites. We were able to detect dimerization of 
AKAP7γ in cells via PCH and estimate the affinity of interaction from the 
concentrations of monomer and dimer. The estimated Kd based on our PCH 
result is approximately 98nM, which is remarkably similar to the Kd of site-two 
(79.7nM) from the fit of our SPR data. Although the affinity of site-one from the 
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SPR analysis is much higher, it is possible that interaction of AKAP7γ with 
endogenous binding partners in the cell alters the affinity of this site, or that 
binding simply cannot occur due to steric hindrance. Our efforts to map the sites 
of binding confirm that two major regions of interaction exist. Interestingly, the 
crystal structure of the common central domain contained in the long AKAP7 
isoforms (amino acids 76-292 of AKAP7δ) does not indicate oligomerization of 
the AKAP (72). This structure lacks the N-terminus of AKAP7γ, which is predicted 
to exist in an unordered arrangement, according to FOLDindex©. Several AKAPs 
have a natively disorganized, unfolded configuration that is hypothesized to aid in 
the docking of a multitude of binding partners (69, 70, 72).  However, this 
unstructured flexibility also significantly hinders conventional structural analysis. 
Hence, this N-terminal domain of AKAP7γ may contribute significantly to its 
oligomerization.  In fact, our peptide array analysis demonstrates that the majority 
of the interacting sequence from 43-98 is not contained in the original crystal 
structure.  Other possible mechanisms include post-translational modification 
driven interactions, and coiled-coil interactions (73-75). Analysis of the AKAP7γ 
sequence using the PredictProtein web site as well as both MARCOIL and 
LOGICOIL web resources support these possibilities for AKAP7γ.  Testing these 
potential mechanisms for oligomerization will help in delineating the means of 
AKAP7γ complex formation. 
 Signaling proteins utilize oligomerization to enhance their known cellular 
functions. One of the better-studied examples is the receptor tyrosine kinase 
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(RTK).  Dimerization of RTKs results in activation and autophosphorylation of 
tyrosine residues on the intracellular domain of the receptor (76, 77).  This step 
initiates the recruitment of other signaling proteins and propagation of signals 
from the receptor to intracellular targets. Though often thought to function in a 
monomeric state, a number of G-protein coupled receptors (GPCRs) have been 
shown to form both homo- and hetero-dimers, often resulting in enhanced activity 
(57).  
 The consequences of AKAP oligomerization are still unclear, but may 
affect multiple processes.  Mass spectrometry analysis of the AKAP5 complex 
suggests that upon dimerization, AKAP5 associates with four calcineurin 
phosphatase heterodimers, and two calmodulin molecules (69).  By increasing 
the concentration of the phosphatase in a localized area, it is suggested that 
AKAP5 can generate specific pools of second messenger-mediated events at the 
plasma membrane. How this change in stoichiometry affects substrate 
dephosphorylation or kinetics of enzyme activation has not been investigated.   
However, other studies of the native AKAP5 complex in hippocampal neurons 
suggest this increase in stoichiometry is an in vitro artifact, as no increase in 
stoichiometry was detected in vivo (78). Oligomerization may also affect 
regulation of intrinsic enzymatic activity of an AKAP.  AKAP-Lbc is a guanine 
nucleotide exchange factor (GEF) for RhoA (79).  Disruption of AKAP-Lbc 
dimerization dramatically increased its GEF activity, suggesting that oligomer 
formation acts to limit the basal activity of the AKAP (71).  However, AKAP7γ 
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does not display any known intrinsic enzymatic activity, suggesting this 
mechanism is not applicable. 
 To explore the possible functional significance of AKAP7γ oligomerization, 
we created a computational model of PKA scaffolding. Significant work has 
demonstrated that release of active Ca subunit from the PKA holoenzyme 
requires not only cAMP binding to the RIIα subunit, but also autophosphorylation 
of RIIα (16-18). This leads us to hypothesize that in the context of an AKAP7γ 
oligomer, release of a single Cα subunit can potentiate the release of additional 
Cα via phosphorylation of RIIα present in the oligomer. In the monomeric state, a 
single Cα can stimulate release of only one extra Cα subunit, but, in a dimeric or 
oligomeric state, release of additional Cα subunits is possible. This double 
negative feedback loop ultimately increases substrate phosphorylation due to the 
increased probability of phosphorylation resulting from increased Cα release 
(Figure 2.7). This is simulated by defining activation of PKA in the AKAP7γ 
complex as a probability function in which the chance of activating all Cα 
subunits increases as the number of active Cα subunits within the complex 
increases (Eq. 1). The model suggests that the physiologic consequence of 
AKAP7γ oligomerization could be increased baseline phosphorylation, increased 
magnitude of phosphorylation in comparison to the monomeric state, and 
increased speed of phosphorylation. For the distribution of monomeric and 
dimeric AKAP7γ derived from our PCH experiment, the model predicts a 1.91 fold 
increase in baseline phosphorylation and a 1.77 fold increase in magnitude of  
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Figure 2.7 Double negative feedback model of PKA activation A) Double negative feedback loop. 
In the resting state, Cα is inhibited by RIIα. However, once Cα is activated by cAMP it is able to 
phosphorylate RIIα at Ser-99, which prevents RIIα from inhibiting Cα. B) Illustration of the double 
negative feedback mechanism occurring within a hypothetical trimeric AKAP complex. AKAP 
(light blue helix) recruits PKA (R homodimer, orange; C, light yellow) to a membrane (blue) 
associated target X (red). In the context of this AKAP oligomer, activation of a single Cα is likely 
to phosphorylate RIIα within the complex leading the release of further Cα. This process feeds 
forward, increasing the probability that all Cα within the complex will become active as each 
additional Cα is activated. The increased amount of active Cα also increases the probability of 
target phosphorylation. 
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phosphorylation in comparison to monomer only. It is important to note that our 
finding does not result from an increase in AKAP7γ or PKA concentrations at the 
ER membrane, it reflects the consequence of oligomerization on PKA activity. In 
all simulations the total amount of PKA scaffolded to the membrane by AKAP7γ 
remains the same. The double negative feedback behavior of Cα activation has 
the potential for interesting consequence when considered in a spatial context. 
The free diffusion of active Cα may permit its interaction with AKAP7γ complexes 
that exist beyond the location of its complex of origin. This could enable the 
spatial spread of PKA activation and target phosphorylation similar to that of a 
calcium spark. Spatial spread of the PKA signal in this manner would depend 
upon many factors including: the diffusion coefficient of Cα, the density of AKAP 
complexes, the ability of Cα to re-associate with RIIα, and the spatiotemporal 
fluctuation in cAMP concentration.  
We have discovered an additional component of the AKAP7γ signaling 
complex and demonstrated that dimerization of AKAP may impact 
phosphorylation of PKA substrates.  As several PKA targets of AKAP7γ have 
been identified, including PDE4D, the PP1 inhibitor I-1 and the cardiac calcium 
regulatory protein phospholamban, AKAP7γ oligomerization has the possibility of 
effecting phosphorylation of these endogenous substrates.   
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Abstract 
Changes in heart rate and contractility in response to sympathetic stimulation 
occur via activation of cAMP dependent protein kinase A (PKA), leading to 
phosphorylation of numerous substrates that alter Ca2+ cycling. Phosphorylation 
of these substrates is coordinated by A-kinase anchoring proteins (AKAPs), 
which recruit PKA to specific substrates (29). Phosphorylation of the PKA 
substrate phospholamban (PLB) is a critical determinant of Ca2+ re-entry into the 
sarcoplasmic reticulum and is coordinated by AKAP7δ/γ (27, 43). Here, we 
further these findings by showing that phosphorylation of PLB requires interaction 
with AKAP7δ/γ and that this interaction occurs only when PLB is 
unphosphorylated. Additionally, we find that two mutants of PLB (R9C and Δ14), 
which are associated with dilated cardiomyopathy in humans, prevent 
association with AKAP7δ/γ and display reduced phosphorylation in vitro. This 
finding implicates the AKAP7δ/γ-PLB interaction in the pathology of the disease 
phenotype. Further exploration of the AKAP7δ/γ-PLB association demonstrated a 
phosphorylation state-dependence of the interaction.  Computational modeling 
revealed that this mode of interaction allows for low concentrations of AKAP and 
PKA (100-200nM) to regulate the phosphorylation of high concentratins of PLB 
(50µM). Our results confirm that AKAP7δ/γ binding to PLB is important for 
phosphorylation of PLB, and describe a novel phosphorylation state-dependent 
binding mechanism that explains how phosphorylation of highly abundant PKA 
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substrates can be regulated by AKAPs present at ~100-200 fold lower 
concentrations.  
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Introduction 
 The heart responds to an increase in sympathetic stimulation via 
activation of the cAMP-dependent protein kinase PKA, leading to phosphorylation 
of several key substrates. These substrates mediate Ca2+ entry, release, and 
uptake into intracellular stores.  Phosphorylation therefore allows the heart to 
increase the force contraction and the rate of relaxation by changing the kinetics 
of the Ca2+ transients that underlie these physiological events.   Importantly, 
several key studies have demonstrated that PKA must be compartmentalized 
with its substrate in the heart in order for phosphorylation to occur (80).   This is 
accomplished via A-kinase anchoring proteins (AKAPs), a class of scaffolding 
proteins that compartmentalize PKA with its substrates, thereby forming a 
microdomain of PKA activity.  Importantly, disruption of PKA anchoring using 
global AKAP/PKA disrupting peptides greatly impacts the contractile response of 
the myocyte to sympathetic stimulation, demonstrating the importance of AKAPs 
for regulation of cardiac Ca2+ dynamics (23, 81). 
A key AKAP that plays a role in the regulation of cardiac Ca2+ dynamics is 
AKAP7 (82).  This AKAP has four splice variants (α, β, γ and δ), with a range of 
molecular weights from 18 to 50 kDa (32). AKAP7δ/γ plays an important role in 
the rate of relaxation of the heart via mediating the phosphorylation of the cardiac 
protein phospholamban (PLB) (27).  In its unphosphorylated state, PLB binds to 
the Sarcoplasmic Reticulum Ca2+-ATPase (SERCA2) pump and decreases pump 
action, thus providing a rate-limiting step in the cardiac contraction/relaxation 
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cycle. Phosphorylation of PLB disrupts the PLB/SERCA2 interaction, thereby 
accelerating Ca2+ re-uptake into cardiac stores and allowing for an increase in 
the rate of relaxation.  Importantly, peptide-based disruption of the AKAP7δ-PLB 
interaction in the rat myocyte significantly attenuates the sympathetic-promoted 
phosphorylation of the protein and the increase in Ca2+ re-uptake associated with 
stimulation (27).  It is important to note that AKAP7δ is replaced by AKAP7γ in 
the human and mouse myocyte (44).  Hence, it has been suggested that this 
interaction could be used as a potential drug target in heart failure patients (83).   
  A number of AKAP7δ/γ binding partners with the capacity to influence 
PLB phosphorylation have been identified including protein kinase C (PKC), 
protein phosphatase-1, inhibitor-1 (I-1), and phosphodiesterase 3A (PDE3A) (49, 
84, 85). This evidence provides us with the key elements of the AKAP7δ/γ 
signaling microdomain, which may control PLB phosphorylation. However, one 
particularly critical question exists: how does a low abundance protein like 
AKAP7δ/γ regulate phosphorylation of a very high abundance protein like PLB? 
This question was eloquently posed by Don Bers in his 2002 review of cardiac-
excitation contraction coupling, commenting “…it is less clear how targeting 
would practically work for phospholamban and troponin I phosphorylation (as 
compared with ICa or RyR). This would require very high amounts of the various 
anchoring and signaling proteins because troponin I and phospholamban are 
present at 50µM or higher concentrations and are dispersed widely in the cell 
(86).” 
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The implied assumption of AKAP microdomain signaling is that AKAPs 
remain bound to their respective PKA substrates regardless of the state of the 
complex. If true, such a mechanism would require high concentrations of both 
AKAP and its binding partners that is similar to that of the PKA substrates – but 
the cellular concentration of PKA is not nearly as high as PLB, nor are the 
concentrations of AKAP7δ/γ or its other binding partners (Protein phosphatase 1, 
Inhibitor-1 and Phosphodiesterase4D3) (47, 49, 87-89). However, it is clear that 
the AKAP plays an important role in the phosphorylation of PLB (90).  Here, we 
confirm that binding of PKA to AKAP7δ/γ is required for PLB phosphorylation and 
that deletion of the PKA binding domain on the AKAP7 results in a significant 
reduction in PLB phosphorylation. Importantly, several human mutants of PLB, 
which are known to exhibit decreased phosphorylation and are associated with 
dilated cardiomyopathy, do not interact with AKAP7δ/γ, suggesting that the PLB-
AKAP7δ/γ interaction is necessary for phosphorylation.  Therefore, the question 
remains: how are these AKAP-binding requirements compatible with the efficient 
phosphorylation of large amounts of PLB?  We hypothesized that this could be 
explained by our newly observed phosphorylation state-dependent binding of 
AKAP7δ/γ to PLB. Here, we show that the high affinity association between 
AKAP7δ/γ and PLB is lost upon phosphorylation of PLB. A computation model of 
the detailed biochemical kinetics of the pathway showed that if state-dependent 
binding is included in the reaction network, phosphorylation of high 
concentrations of PLB is possible at low concentrations of both AKAP7δ/γ and 
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PKA, consistent with the observed results (90). Importantly, our experimental 
findings and kinetic analysis provide a mechanistic hypothesis of AKAP7δ/γ 
complex signaling in cardiac myocytes that reconciles the problem with disparity 
of complex component concentrations.  
 
Experimental Methods 
Antibodies 
The following primary antibodies were used for immunoblotting: mouse 
monoclonal Phospholamban (Millipore; 1:1000 dilution), polyclonal phosphor-
phospholaman serine 16 (Millipore; 1:500), mouse monoclonal GFP (Santa Cruz 
Biotechnology; 1:500 dilution), polyclonal mCherry (Thermo Scientific Pierce; 
1:3000 dilution), monoclonal PKA RIIα subunit (Santa Cruz Biotechnology; 1:500). 
Immunoprecipitations were carried out using the following antibodies: polyclonal 
AKAP7 (Sigma; 5µg), mouse monoclonal GFP (Santa Cruz Biotechnology; 5µg), 
mouse monoclonal Phospholamban (Millipore; 3µg) 
 
Expression constructs 
The human phospholamban construct was obtained from Origene and amended 
with EcoRI/BamHI restriction sites using PCR, and subcloned into the peGFP-N1 
vector.  Mutant phospholamban constructions were made by site directed 
mutagenesis. 
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Cell Transfection and Immunoprecipitation 
HEK293 cells were transfected at 50-70% confluency in 60mm plates using the 
calcium phosphate method with 6 µg of each plasmid DNA.  Cells were treated 
with various drugs for the time specified, and cell lysate was collected in 0.5ml 
HSE buffer (HEPES, pH 7.4, 150mM NaCl, 5mM EDTA, 1% Triton X-100 and 
protease inhibitors).  Supernatants were incubated overnight at 4°C with the 
indicated antibody and 15ml of prewashed protein A-or G-agarose. Following 
extensive washing, captured proteins were solubilized in 2X sample buffer and 
analyzed by immunoblot.  
 Rat heart extract was prepared as previously described (26, 91).  
Immunoprecipitating antibodies were added to 500µl of extract along with 13µl 
protein agarose.  After an overnight incubation followed by extensive washing, 
captured proteins were analyzed by immunoblot. 
 
In vitro Phospholamban phosphorylation assays 
Various PLB peptides (1µg) were incubated in kinase buffer (50mM Tris-HCL pH 
7.5, 5mM MgCl2) containing 100mM ATP, 5mM [γ-32]ATP and 800 units of 
purified PKA catalytic subunit (NEB).  After a 15 minute incubation at 30°C, the 
reaction mixture was spotted onto phosphocellulose strips and washed five times 
in 75mM phosphoric acid.  Filters were air dried and counted. 
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Rat neonatal myocyte culture 
Myocytes were prepared from 2 day old Sprague-Dawley rats, as previously 
described.  Cell were plated in Dulbecco’s Modified Eagle medium (DMEM)with 
17% Media 199, 1% penicillin/streptomycin solution, 10% horse serum and 5% 
fetal bovine serum (FBS) at 125,000 per cm2.  After an overnight incubation in 
plating medium, the myocytes were maintained in culture for up to one week in 
maintenance medium (79% DMEM, 20% Media 199, and antibiotic).    Cells were 
stimulated with the various drugs as described. 
 
Surface Plasmon Resonance 
SPR analysis was performed using a BIAcore T100. Biotinylated-
Phospholamban peptide (Chi Scientific) was covalently immobilized using NHS 
(N-hydroxysuccinamide) and EDC [1-ethyl-3-(3-
(dimethylamino)propyl)carbodiimide] (Biacore amine coupling kit) to the surface 
of a sensor chip (BIAcore type CM5). The amount of ligand bound (in resonance 
units, RUs) was 300 RU. AKAP7γ protein analyte was diluted at increasing 
concentrations (25–100 nM) in HBS buffer (10 mM HEPES (pH 7.4), 150 mM 
NaCl, and 0.005% Surfactant P20) and injected over the sensor surface at a flow 
rate of 30 µL/min for 300 seconds. Post injection phase, dissociation was 
monitored in HBS buffer for 300 seconds at the same flow rate. The surface was 
regenerated between injections using 10 mM NaCl at a flow rate of 50 µL/min for 
30 seconds. Sensorgrams were all processed by BIAcore T100 evaluation 
software. 
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GST-RII pulldown assay 
Beads charged with RIIα-GST fusion protein were incubated with isolated cell 
lysate transfected as described above.  After an overnight incubation at 4C with 
shaking, beads were washed extensively and captured proteins were solubilized 
in 2X sample buffer and analyzed by immunoblot. 
 
Computational Modeling of the AKAP7-Phospholamban complex. 
An ordinary differential equation (ODE) model of PLB phosphorylation by 
AKAP7δ/γ bound PKA was implemented using the Virtual Cell modeling software. 
The reaction network is composed two basic modules; 1) cAMP production and 
PKA activation and 2) AKAP7δ/γ binding and phosphorylation of PLB with a total 
of 18 species and 14 reactions (Table 1, Fig S1). Activation of AC via association 
with Gs in module 1 results in the production of cAMP that binds PKA (R2C2) 
resulting in sequential dissociation of each of two catalytic subunits (C). Free C is 
able to phosphorylate Gs within the GsAc complex resulting in the inhibition of 
cAMP production and, in conjunction with the activity of PDE, the return of cAMP 
levels to baseline. Due to the high affinity interaction of cAMP with the PKA 
regulatory subunit (R), C does not reassociate with R to form PKA (R2C2) 
following cAMP stimulation. In order to return PKA activity to baseline following 
stimulation we allowed cAMP bound R (R2_cAMP) to be stripped of cAMP by 
PDE (reference). In the second module of the reaction network PLB associates 
with AKAP to form a complex (AKAP_PLB) followed by phosphorylation of PLB 
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(AKAP_pPLB). All AKAP is bound to PKA derived from the total pool of PKA in 
module 1. Since AKAP bound PKA activity represents only a fraction of the total 
PKA activity, the total AKAP-PKA activity is defined by the following equation: 
𝐸 = 2 ∗ 𝐴𝐾𝐴𝑃_𝑃𝐿𝐵 ∗ 𝐶2 ∗ 𝑅2𝐶2+ 𝑅2𝐶1+ 𝐶  
where E represents the total amount of enzyme (active PKA) from the AKAP 
bound pool of PKA that is available to participate in the phosphorylation of PLB 
which, is defined by standard Michaelis-Menten kinetics: 
𝑝𝑃𝐿𝐵 =    𝐸 ∗ 𝑘!"# ∗ [𝐴𝐾𝐴𝑃_𝑃𝐿𝐵](𝐾𝑚 + 𝐴𝐾𝐴𝑃_𝑃𝐿𝐵 )  
To simulate the difference between phosphorylation state-dependent (AKAP 
does not bind pPLB) and phosphorylation state-independent (AKAP binds both 
PLB and pPLB) the reverse rate for the interaction of AKAP and pPLB was 
modulated so that AKAP bound pPLB with either equal or lower affinity than PLB.  
For state-independent binding, the affinity of AKAP for pPLB is the same as in 
the non-phosphorylated state and for state-dependent binding the forward rate 
was increased. For state-dependent binding to PLB the reverse rate of the 
AKAP-pPLB interaction was increased by a factor of 1000, changing the affinity 
from 13.3nm to 13.3µM. The model is available in the public biomodels folder of 
the Virtual Cell software. 
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Results 
AKAP7γ directly binds to phospholamban  
 Due to conflicting evidence demonstrating the importance of AKAP7δ/γ for 
phospholamban (PLB) phosphorylation (27, 90), we investigated the dynamics of 
AKAP7δ/γ binding to PLB as a possible regulatory function of phosphorylation.  
To begin with, we confirmed previous findings that AKAP7δ/γ binds directly to 
PLB (27).  As shown in Figure 3.1A, PLB co-immunoprecipitated with AKAP7δ/γ 
from isolated rat heart extract, but not with control IgG, demonstrating that these 
two proteins form a complex in cardiac myocytes.  Next, we investigated if this 
interaction was specific for the cardiac myocyte, or if association could be 
detected in a heterologous system. HEK293 cells were transfected with plasmids 
expressing mCherry-AKAP7γ in the presence and absence of GFP-
phospholabman.  GFP was immunoprecipitated and the association of 
AKAP7γ was determined by Western blot analysis (Figure 3.1B).  Importantly, co-
precipitation of mCherry-AKAP7γ was only seen in cells expressing GFP-PLB, 
demonstrating the specificity of the interaction.  To further these findings and 
examine the kinetic properties of the interaction, we performed surface plasmon 
resonance (SPR).  As the domain on phosholamban for binding to AKAP7γ is 
maintained in the first 21 amino acids, we immobilized a peptide mimicking this 
domain on a CM5 sensor chip.  Varying concentrations of purified AKAP7γ were 
used to determine the dynamics of the interaction.  As shown in Figure 3.1C, we 
confirmed a direct interaction between phospholamban and AKAP7γ with an  
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Figure 3.1 Direct cellular interaction between AKAP7δ/γ and phospholamban. 
A) AKAP7γ was immunoprecipitated from rat heart extract and association of PLB was 
determined by Western Blot. n=3. B) mCherry Western blot analysis of anti-GFP 
immunoprecipitates isolated from HEK-293 cells co-transfected with mCherry-AKAP7γ in the 
presence and absences of GFP-PLB (upper panels). To confirm immunoprecipitation of equal 
amounts of GFP-PLB, the nitrocellulose membranes were also probed for GFP using a 
monoclonal anti-GFP antibody (middle panel).  Lower panels depict mCherry and GFP Western 
blot analysis of the input (20µL) from each condition. n=3. C) SPR was performed by immobilizing 
a peptide containing the first 21 amino acids of PLB (150RUs) on a CM-5 chip and measuring the 
response when passing over a range of concentrations (25-100nM) of AKAP7γ. Forward and 
reverse rates of binding and binding affinity were determined by fitting of the sensorgram with 
BIAcore T100 evaluation software.   
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affinity of 13.3nM.  Analysis of the fit of the interaction suggests one site of 
interaction.   Taken together, these data confirm the original observation 
demonstrating a direct association of AKAP7γ with phospholamban that can be 
isolated from cardiac myocytes. 
PKA bound to AKAP7δ/γ is responsible for phosphorylation of phospholamban 
 The primary purpose of AKAPs is to co-localize PKA and its substrate via 
formation of a multi-component signaling complex, resulting in enhanced 
substrate phosphorylation. Therefore, we next examined the necessity of PKA 
binding to AKAP7δ/γ for PLB phosphorylation.  To investigate this association in 
an endogenous tissue, PLB was immunoprecipitated from rat heart lysate, and 
association with PKA was determined in the presence or absence of the 
AKAP/PKA disrupting peptide AKAP-IS (Figure 3.2A) (15).  Disruption of PKA 
anchoring using the AKAP-IS peptide decreased association of the PKA RII 
subunit with PLB.  Importantly, incubation of a control peptide did not significantly 
affect PKA/PLB interaction, demonstrating that PKA associates with PLB via 
interaction with AKAP.  To determine the role of AKAP7γ in mediating this 
association, HEK293 cells were transfected with GFP-PLB and either wild-type 
mCherry-AKAP7γ, or one lacking the PKA binding domain (mCherry-DPKA-
AKAP7γ).  Lysate isolated from these cells was subjected to pulldown analysis 
using GST-tagged PKA RIIα subunit.  This is a common technique used to 
isolate AKAP complexes from various tissues, as the RII subunit will pulldown the 
AKAP and all AKAP-associated proteins (49, 69).  As shown in Figure 3.2B,   
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Figure 3.2 AKAP7δ/γ anchors PKA to the phospholamban complex to enhance phosphorylation. 
A) PLB was immunoprecipitated from rat heart lysate.  Following extensive washing, the 
immunoprecipitates were incubated with the AKAP/PKA disrupting peptide AKAP-IS (10µM) or 
control peptide  (10µM) for 30 minutes while rocking. After another round of washing, association 
of the regulatory subunit of PKA was determined by Western blot. B) HEK-293 were transfected 
with GFP-PLB and either wild-type mCherry-AKAP7γ, or one deficient in the PKA binding domain 
(mCherry-ΔPKA-AKAP7γ).  Isolated lysates were subjected to pulldown assays using bacterially 
purified GST-tagged PKA RII subunit precharged on Glutatione-agarose; Both GFP and mCherry 
antibodies were used for detecting PLB and AKAP7γ interactions, respectively (upper panel). 
Protein stain of the nitrocellulose membrane before Western blot analysis is shown in the middle 
panel. Input from the transfected cells (20µl) is shown in the bottom panels. n=3.  C) HEK-293 
were transfected with GFP-PLB and either wild-type mCherry-AKAP7γ, or one deficient in the 
PKA binding domain (mCherry-ΔPKA-AKAP7γ).  Cells were stimulated with 100µM Isoproterenol 
for 5 minutes before cell lystate was isolated and loaded onto and SDS-PAGE gel.  
Phosphorylation of PLB at Serine 16 was determined using a phospho-specific antibody (upper 
panel).  Total expression of the proteins is shown in the lower panels using both GFP and 
mCherry antibodies to detect PLB and AKAP7γ, respectively. n=3 
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GFP-PLB only associated with the PKA subunit in the presence of full-length 
AKAP7γ.  However, when the PKA binding domain was deleted from the AKAP, 
GST-RIIα could no longer pulldown PLB, demonstrating the importance of PKA  
anchoring to AKAP7γ. Taken together, these results implicate AKAP7γ for linking 
the kinase to the PLB complex.   
 Next, we investigated the functional significance of this interaction for 
regulation of PLB phosphorylation.  We first performed analogous experiments to 
those outlined in Figure 3.2B, and looked at the role of AKAP7γ-bound PKA on 
PLB phosphorylation.  As shown in Figure 3.2C, expression of the anchoring 
protein dramatically heightened PLB phosphorylation.  However, when the PKA 
binding domain was deleted from the AKAP, this enhancement was lost, 
suggesting that the kinase must be attached to the AKAP for this effect.  
 
Described human mutations of phospholamban contained in the AKAP7δ/γ 
binding domain decrease complex formation, thereby reducing phosphorylation  
 Multiple mutations of PLB have been identified and linked to familial 
dilated cardiomyopathy.  At least two of these mutations are found in the 
AKAP7δ/γ binding domain, suggesting these mutation may affect the ability of 
PLB to bind to the AKAP7δ/γ (Schematic diagram shown in Fig 3.3A). Mutation of 
Arginine 9 to Cystine (PLB-R9C) displays a dose-dependent inhibition of 
SERCA2a and significantly decreased phospho-PLB (92).  The other mutation 
found in the AKAP7δ/γ binding region is a deletion of Arginine 14 (PLB-Δ14), 
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which exhibits super-inhibition of SERCA2a activity, correlating with decreased 
PLB phosphorylation (93).  To test the importance of AKAP7δ/γ binding to PLB 
for the phosphorylation of PLB, we utilized these mutations to block association. 
We investigated whether or not these mutations affect the ability of the complex 
to form in a cellular environment.   AKAP7γ was coexpressed in HEK293 with 
wild-type PLB-GFP, or one of the mutated isoforms (PLB-R9C-GFP or PLB-Δ14-
GFP).  The PLB-GFP complex was isolated and association of AKAP7γ-mCherry 
was determined by Western Blot.   As shown in Figure 3.3B, both mutations 
significantly decreased the co-precipitation of AKAP7γ, suggesting that a 
decrease in the AKAP7γ binding affinity measured in these mutants results in 
decreased association of AKAP7γ with the protein in a cellular context.  
 Importantly, the decrease in complex formation seen with the PLB mutants 
should reduce the concentration of PKA found in the PLB complex.  To test this 
hypothesis, AKAP7γ was coexpressed in HEK293 with wild-type PLB-GFP, or 
one of the mutated isoforms (PLB-R9C-GFP or PLB-Δ14-GFP).  Cell lysate was 
subjected to GST-RII pulldown, and association of GFP-PLB was measured.  In 
confirmation of our findings, wild-type PLB associates with the PKA subunit when 
co-expressed with AKAP7γ (Figure 3.3C).  However, both PLB mutations showed 
decreased association with the GST-RII, suggesting mutation of PLB in the 
AKAP7δ/γ binding domain decreases complex formation and reduces PKA 
association with PLB.  As our hypothesis states that AKAP7δ/γ anchored PKA 
mediates the phosphorylation of PLB, the decrease in complex  
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Figure 3.3 Described human mutations of phospholamban disrupt AKAP7γ binding 
A) Schematic depiction of the mutations found in phospholamban that are found in the AKAP7δ/γ 
binding domain. B) mCherry Western blot analysis of anti-GFP immunoprecipitates isolated from 
HEK-293 cells co-transfected with mCherry-AKAP7γ and either wild-type GFP-PLB, or one of the 
mutated isoforms (PLB-RC9-GFP, or PLB-Δ14-GFP, upper panels). To confirm 
immunoprecipitation of equal amounts of GFP-PLB, the nitrocellulose membrane was also probed 
for GFP using a monoclonal anti-GFP antibody (middle panel).  Lower panels depict mCherry and 
GFP Western blot analysis of the input (20µL) from each condition. n=3. C) HEK-293 were 
transfected with mCherry-AKAP7γ and either wild-type GFP-PLB, or one of the mutated isoforms 
(PLB-RC9-GFP, or PLB-Δ14-GFP, upper panels).   Isolated lysates were subjected to pulldown 
assays using bacterially purified GST-tagged PKA RII subunit precharged on Glutatione-agarose; 
Both GFP and mCherry antibodies were used for detecting PLB and AKAP7γ interactions, 
respectively (upper panel). Protein stain of the nitrocellulose membrane before Western blot 
analysis is shown in the middle panel. Input from the transfected cells (20µl) is shown in the 
bottom panels. n=3.  D) HEK-293 were transfected with mCherry-AKAP7γ and either wild-type 
GFP-PLB, or one of the mutated isoforms (PLB-RC9-GFP, or PLB-Δ14-GFP.   Cells were 
stimulated with 100µM Isoproterenol for 5 minutes before cell lystate was isolated and loaded 
onto and SDS-PAGE gel.  Phosphorylation of PLB at Serine 16 was determined using a phospho-
specific antibody (upper panel).  Total expression of the proteins is shown in the lower panels 
using both GFP and mCherry antibodies to detect PLB and AKAP7γ, respectively. n=3 E) PLB 
peptides (1µg) were incubated in kinase buffer (50 mM Tris-HCL pH 7.5, 5 mM MgCl2) containing 
100 mM ATP, 5 mM [γ-32]ATP and 800 units of purified PKA catalytic subunit (NEB).  After a 15 
inute incubation at 30°C, the reaction mixture was spotted onto phosphocellulose strips and 
washed five times in 75 mM phosphoric acid.  Filters were air dried and counted. 
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formation seen with the mutated isoforms of PLB should therefore result in a 
decrease in phosphorylation of the protein.  To test this hypothesis, AKAP7δ/γ 
was coexpressed in HEK293 with wild-type PLB-GFP, or one of the mutated 
isoforms (PLB-R9C-GFP or PLB-Δ14-GFP).  Cells were stimulated with 100nM 
Isoproterenol for 5 minutes, and phosphorylation of PLB was determined by 
Western Blot analysis  (Figure 3.3D).  In conjunction with those results seen in 
both transgenic animals and human patients (92, 93), less phosphorylation was 
seen with the mutated isoforms of PLB. This finding correlates with the 
decreased PKA association within the mutant complexes due to deceased 
affinities for AKAP7γ, suggesting that one mechanism for the attenuation of 
phosphorylation of the mutant PLB isoforms is a significant decrease in the 
localization of the kinase to the complex.  However, it is plausible that this effect 
may result from a decreased ability of these mutated isoforms to be 
phosphorylated by the kinase and not a disruption in the localization of the kinase 
to the PLB complex.  To test this, peptides mimicking the first 21 amino acids of 
wild-type PLB, PLB-R9C or PLB-Δ14 were subjected to an in vitro kinase assay.  
As shown in Figure 3.3E, all peptides were able to be phosphorylated by the 
kinase to a similar extent, suggesting the decrease in phosphorylation of the 
mutated PLB isoforms seen in the exogenous system is not due to a lack of 
ability of the kinase to phosphorylate the mutated isoforms.  Taken together, the 
data shown in Figure 3.3 supports the hypothesis that by linking the kinase to its 
substrate PLB, AKAP7δ/γ mediates phosphorylation of PLB. 
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Figure 3.4 Phosphorylation of PLB significantly decreases the affinity for AKAP7δ/γ. A) HEK-293 
were transfected with GFP-PLB and mCherry-AKAP7γ.  Cells were stimulated with 100µM 
Isoproterenol for 5 minutes and the PLB complex was isolated by immunoprecipitation using anti-
GFP. Association of AKAP7γ was determined by Western blot using anti-mCherry (upper panels). 
To confirm immunoprecipitation of equal amounts of GFP-PLB, the nitrocellulose membrane was 
also probed for GFP using a monoclonal anti-GFP antibody (middle panel). Total expression of 
the proteins is shown in the lower panels using both GFP and mCherry antibodies to detect PLB 
and AKAP7γ, respectively. Phosphorylation of PLB at Serine 16 in total lysate was determined 
using a phospho-specific antibody (upper panel). n=3 B) Rat neonatal cardiac myocytes were 
stimulated with 10µM Isoproterenol for 5 minutes and the PLB complex was isolated by 
immunoprecipitation. Association of AKAP7δ/γ was determined by Western blot (upper panel). 
Total expression of the proteins is shown in the lower panels.  Phosphorylation of PLB at Serine 
16 in total lysate was determined using a phospho-specific antibody (upper panel). n=3  
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Phosphorylation of phospholamban decreases the affinity for AKAP7δ/γ binding 
 Contained in the AKAP7δ/γ binding domain on PLB is the PKA 
phosphorylation site.  We therefore proposed that phosphorylation of PLB would 
decrease the ability of the AKAP to interact with the protein.  To test this 
hypothesis, we began by defining the change in affinity between phosphorylated 
PLB and non-phosphorylated PLB using SPR.   We immobilized a peptide 
mimicking the first 21 amino acids of either wild-type PLB, or one that is 
permanently phosphorylated at Serine 16 to a CM5 sensor chip, and then  
determined the kinetic strength of the two interactions using varying 
concentrations of purified AKAP7γ.  As shown in Figure 3.4A, when 
phosphorylated, the affinity of AKAP7γ and PLB is below the limit of detection, 
suggesting a low affinity binding.  To confirm this finding in a cellular context, 
HEK293 cells were transfected with plasmids expressing mCherry-AKAP7γ and 
GFP-PLB.  After a 15 minute stimulation with 100nM Isoproterenol, GFP was  
immunoprecipitated and the association of AKAP7γ was determined by Western 
blot analysis (Figure 3.4B).  Importantly, co-precipitation of mCherry-AKAP7γ was 
dramatically decreased under conditions that result in phosphorylation of PLB.  
These findings were confirmed in an endogenous setting. Rat neonatal myocytes 
were stimulated with 10µM Isoproterenol for 15 minutes followed by 
immunoprecipitation of phospholamban and blotting for AKAP7γ. Association of 
AKAP7γ with PLB was not detected following isoproterenol stimulation. Taken 
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together, these findings suggest that the AKAP7δ/γ interaction with PLB is 
dispersed upon activation of PKA and phosphorylation of PLB. 
 
Phosphorylation state specific binding of AKAP7δ/γ increases phospholamban 
phosphorylation 
 Our finding that the AKAP7δ/γ-PLB interaction is phosphorylation state 
specific is interesting given that the purpose of this interaction is to direct PKA 
phosphorylation to PLB. Such state selective binding suggests that AKAP7δ/γ 
likely binds, phosphorylates, and then unbinds PLB in a dynamic process. Thus 
state-selective binding has the potential to increase PLB phosphorylation in 
comparison to non-state-specific binding. 
 To investigate the potential consequence of state specific binding of 
AKAP7δ/γ to PLB, we created an ordinary differential equation model that 
simulates phosphorylation of PLB by AKAP7δ/γ bound PKA at baseline steady 
state and during cAMP stimulation. For all iterations of the model parameters, the 
simulation was run for 15000s prior to initiating our stimulation protocol, thus 
ensuring that all species reach a baseline steady state. At baseline steady state, 
the level of cAMP is 244nm and 2.4% of the total PKA is in an active state. 
Following initiation of our stimulation protocol, the levels of cAMP rise to 5.6mM 
activating 94.1% of the total PKA in 90s and decaying back to baseline in roughly 
500-600s (Figure 3.5A). To test the effect of state specific binding, we compared 
the levels of phospho-PLB with either equal affinity of AKAP for PLB and  
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Figure 3.5 State dependent binding of AKAP to PLB dramatically increases PLB phosphorylation 
upon stimulation. A) cAMP concentration and PKA activity over the time-course of the simulations. 
All species in the model are at steady state prior to stimulation (t = 0s), which was achieved via 
activation of additional AC. B) pPLB concentration at baseline and maximum following stimulation 
for state independent binding of AKAP and PLB. C) pPLB concentration at baseline and 
maximum following stimulation for state dependent binding of AKAP and PLB. D) Dynamic range 
(𝐷𝑦𝑛𝑎𝑚𝑖𝑐  𝑅𝑎𝑛𝑔𝑒 =    !"#  !"#$!!"#  !"#$!"#$%  !"#  ) of PLB phosphorylation for both state dependent and 
state independent binding of AKAP to PLB. The y-axis is on a log2 scale to enable viewing of both 
trends on the same graph. 
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phospho-PLB (state-independent), or 1000-fold lower affinity for pPLB (state-
dependent). We tested AKAP concentrations ranging from 1-250nM for both 
state-independent binding and state-dependent binding. Unpublished analysis 
from our lab suggests that the level of AKAP7δ/γ present in cardiac myocytes is 
roughly 100nm. The total amount of PLB present in these simulations is 50µM 
(86). In the range of AKAP concentrations tested, state-independent binding of 
AKAP to PLB provides minimal capacity for PLB phosphorylation, with very low 
levels of phosphorylation at baseline and minimal response to stimulation (Figure 
3.5B). We quantified the response to stimulation by calculating the dynamic 
range, defined as the change in concentration of phospho-PLB from baseline to 
maximum, divided by the total concentration of PLB. The dynamic range for 
state-independent binding ranges from 0.01% to 0.17% (Figure 3.5C). State-
dependent binding of AKAP to PLB however, allows for maintenance of low 
baseline levels of PLB phosphorylation and dramatic responses to stimulation 
(Figure 3.5B). With state-dependent binding, the dynamic range varies from 
0.05% to 42.3% (Figure 3.5D). It is important to note that while the primary 
determinants of the dynamic range of PLB phosphorylation are the affinity of 
AKAP for phospho-PLB and the AKAP concentration, the dynamic range is also 
modified significantly by baseline cAMP concentration and the amount of 
phosphatase present in the system. Higher baseline concentrations of cAMP 
(622nm) contribute to increased baseline activity of PKA and hence higher 
concentrations of phospho-PLB (Figures 3.6A and 3.6B). With the same level of  
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Figure 3.6 Increased baseline cAMP reduces dynamic range of PLB phosphorylation  
A) cAMP concentration and PKA activity over the time-course of the simulations as in figure 5. 
The concentrations of AC and PDE have been adjusted to increase the baseline level of cAMP 
from 244nm to 622nm. B) pPLB concentration at baseline and maximum following stimulation for 
state dependent binding of AKAP and PLB. C) Dynamic range of PLB phosphorylation for state 
dependent phosphorylation at low (244nM) and high (622nM) baseline cAMP  levels given AKAP 
concentrations ranging from 1nM to 250nM. D) Dynamic range of PLB phosphorylation with high 
baseline levels of cAMP and normal or increased protein phosphatase (PP). 
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stimulation, this results in a decreased dynamic range (Figure 3.6C). Additionally, 
it was noted that at higher baseline cAMP concentrations, increasing the AKAP 
concentration past 0.15mM resulted in dramatic increases in baseline phospho-
PLB. While this threshold effect of AKAP concentration on baseline phospho-PLB 
will occur in the simulations with lower baseline cAMP concentrations, it requires 
higher concentrations of AKAP than we would expect to see in vivo. We 
determined that this is primarily due to a shift in the balance of PKA and 
phosphatase activity. Increasing the amount of phosphatase in the simulations 
allowed for maintenance of lower baseline phospho-PLB concentrations for 
AKAP concentrations at the top of our range, and slightly reduced maximal 
phospho-PLB for all AKAP concentrations. This resulted in a reduced dynamic  
range at lower AKAP concentrations, yet increased the dynamic range at higher 
AKAP concentrations in comparison to simulations with a lower phosphatase 
concentration (Figure 3.6D). The model demonstrates that phosphorylation state-
dependent binding of AKAP7δ/γ to PLB could allow low concentrations of 
AKAP7δ/γ to phosphorylate much higher concentrations of PLB. Additionally, the 
data suggests that the significant increase in dynamic range seen with state-
dependent binding is stable over a range of baseline cAMP and phosphatase 
concentrations, perhaps allowing for fine-tuning of AKAP7δ/γ complex signaling. 
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Discussion 
 The importance of AKAP7δ/γ to PLB phosphorylation and cardiac calcium 
dynamics has recently been called into question by the work of Jones et al (90). 
Their AKAP7 PKA binding domain knockout mouse displayed no obvious 
phenotype, nor any defect in PLB phosphorylation or Ca2+ handling in response 
to sympathetic stimulation.  Hence, the authors suggest that AKAP7 is not 
responsible for anchoring PKA to PLB, and suggest that another AKAP likely 
performs this function.  Their deletion construct is expected to ablate only the 
PKA and Cav1.2 binding domains of all AKAP7 isoforms, although no effect on L-
type calcium current was seen.  It is concerning that the authors did not 
demonstrate that the truncated protein products do not associate with PKA.  
Additionally, it is noteworthy that previous work by this group found that complete 
ablation of AKAP5 in mice does not show an obvious phenotype, while specific 
ablation of the PKA binding domain does (94).  It is possible that deletion of exon 
7 behaves more like a full length AKAP7-knockout, which is consistent with the 
lack of detection of all isoforms of the AKAP in this model.  Additionally, if a 
truncated version of AKAP7δ/γ is still expressed in the mouse, it would still bind 
all the other components of the complex and perhaps the balance of 
phosphorylation to dephosphorylation is changed.  Further investigation of this 
mouse model is warranted before concluding that AKAP7δ/γ anchoring to PKA is 
not important.However, the data shown here clearly demonstrates the role of 
AKAP7δ/γ in mediating phosphorylation of PLB.  AKAP7δ/γ was first identified as 
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the AKAP that directs PKA mediated phosphorylation of PLB by Lygren et al in 
2007. This work showed that disruption of the AKAP7δ-PKA interaction results in 
a reduction in PLB phosphorylation by approximately 50% and that this has a 
significant effect on Ca2+ dynamics (27). Our work confirms this finding by 
showing that disrupting PKA binding to the complex, or decreasing the affinity for 
AKAP7δ/γ and PLB reduces PKA phosphorylation of PLB.  Hence, AKAP7δ/γ 
should be a key player in the calcium dynamics of the heart. 
Several human PLB mutations have been discovered that are associated 
with dilated cardiomyopathy. Two PLB mutants in particular, PLB-R9C and PLB-
Δ14, display hypo-phosphorylation, yet the mechanism of the decrease in 
phosphorylation is unclear at present (92, 93). We examined the ability of these 
PLB mutants to associate with AKAP7γ and found a significant reduction in PKA 
association with the complex and a reduction in phosphorylation of the mutant 
proteins when compared to wild-type PLB in cells. Together, these findings 
suggest that hypo-phosphorylation associated with the human PLB mutants is 
most likely due to impaired interaction with AKAP7δ/γ. Given the clinically 
significant phenotype associated with these mutants, our findings indicate that 
the AKAP7δ/γ-PLB interaction is critically important for maintaining PLB 
phosphorylation and normal cardiac function in humans. 
 Phosphorylation of PLB by PKA occurs at S16, which is located within the 
region of the AKAP7δ/γ binding site. The location of this phosphorylation site 
suggests that it may affect AKAP7δ/γ binding to PLB. Our attempts to detect 
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AKAP7δ/γ-pPLB binding indicated a lack of association in both transfected cells 
and stimulated rat neonatal myocytes. This finding is very interesting, and 
suggests that the AKAP7δ/γ-PLB interaction may be very dynamic. Given the 
phosphorylation dependence of this binding interaction, AKAP7γ may work by 
essentially shuttling PKA from one PLB molecule to the next as it binds, directs 
phosphorylation, and then unbinds to find its next unphosphorylated target. This 
sort of interaction has the potential to greatly amplify PLB phosphorylation. 
To confirm whether the new finding of phosphorylation state binding 
dependency on PLB phosphorylation could in fact have such an amplification 
effect, we created an ordinary differential equation model of the complex 
dynamics. For AKAP-PLB interactions that are phosphorylation state-
independent, the ability to achieve complete PLB phosphorylation would require 
at least an equimolar ratio of AKAP to PLB, since each PLB molecule would need 
an associated AKAP-PKA complex. In the range of AKAP concentrations tested, 
our model suggests that state-independent binding of AKAP to PLB cannot 
achieve levels of PLB phosphorylation that would allow for effective modulation of 
SERCA2a activity. Furthermore, the results suggested that state-independent 
binding would be insensitive to stimulation given that the dynamic range of 
phosphorylation with the maximum amount of AKAP tested is only ~0.2% of the 
total PLB concentration. However, state-dependent binding of AKAP to PLB 
enables low concentrations of AKAP7γ to direct phosphorylation of much higher 
concentrations of PLB. While the concentration of PLB is suggested to be 50µM 
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or greater in cardiac myocytes, only 10-20% of the total PLB is in the monomeric 
form that can interact with and inhibit SERCA2a (43, 86). Our simulations show 
that at physiologically relevant concentrations of AKAP7δ/γ a dynamic range of 
PLB phosphorylation can be achieved such that complete phosphorylation of 
monomeric PLB is possible. Thus, phosphorylation state-specific binding could 
explain the ability of low concentration proteins like AKAP7γ to regulate 
phosphorylation of high concentration proteins like PLB and troponin.  
Data from our model also highlights the importance of the balance 
between AC and PDE activity, as well as PKA and phosphatase activity. The 
level of cAMP present in a given AKAP domain clearly defines the maximum 
dynamic range possible, as increased baseline cAMP results in higher baseline 
PKA activity resulting in a narrowed dynamic range of phosphorylation. While the 
increased baseline phosphorylation may be tempered by increased phosphatase 
activity, this too results in a slight decrease in the dynamic range of 
phosphorylation. Importantly, the significant increase in dynamic range seen with 
state-dependent binding, in comparison to state-independent binding, still exists 
with variation in baseline cAMP and phosphatase concentration. 
This also raises a particularly intriguing hypothesis that such a mechanism 
may allow the cell to adapt to fluctuations in baseline cAMP concentration. As 
cAMP concentrations rise, additional phosphatase could restore baseline levels 
of phosphorylated substrate while still allowing for a sufficient dynamic range to 
provide a detectable signal. This important role of phosphatase in the dynamic of 
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PLB phosphorylation is consistent with several published results demonstrating 
the importance of phosphatase inhibition for PLB phosphorylation, lending further 
credence to these findings (95-97). 
Our findings reaffirm the importance of AKAP7δ/γ in directing 
phosphorylation of PLB and present a novel mechanism that can explain the 
decrease in PLB phosphorylation associated with human PLB mutants. The 
state-dependent binding of AKAP7δ/γ also explains how it may be possible that 
low concentrations of AKAP and PKA could regulate phosphorylation of high 
concentrations of substrate, as is the case for PLB and troponin. These findings 
require us to consider that AKAP complexes in general may be much more 
dynamic than previously thought. Further investigation of the AKAP7γ-PLB 
complex kinetics is warranted, as well as careful examination of other AKAP 
complexes that may also exhibit similar state-dependent interactions. 	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Langevin Dynamic Simulation of AKAP-PKA Complex: Re-envisioning the 
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Abstract 
The second messenger cAMP and its effector cAMP-dependent protein kinase A 
(PKA) constitute a ubiquitous cell signaling system. In its inactive state PKA is 
composed of two regulatory subunits that dimerize, and two catalytic subunits 
that are inhibited by the regulatory subunits. Activation and release of the 
catalytic subunits occurs upon binding of two molecules of cAMP to each 
regulatory subunit. Although many receptor types existing within the same cell 
may use this signaling system, compartmentation of signaling does occur due to 
A-Kinase Anchoring Proteins (AKAPs), which act to co-localize PKA with specific 
substrates. The molecular mechanism allowing AKAPs to direct PKA 
phosphorylation to a particular substrate remains unknown. This is primarily due 
to the large body of evidence suggesting that the catalytic subunit, which is highly 
diffusable, is released in response to cAMP. Recent evidence from Smith et al 
suggests that in the cell, the catalytic subunit may not be released from the AKAP 
complex (52). They further demonstrated that alterations in the structure of the 
PKA regulatory subunit tether affect substrate phosphorylation. We use novel 
computational software based on Langevin dynamics, Langdyn, to simulate the 
AKAP-PKA complex in order to determine a molecular mechanism for the 
changes in phosphorylation seen with alteration in tether length and flexibility, 
and also to demonstrate whether or not AKAPs can effectively direct PKA 
phosphorylation to a particular substrate upon release of the catalytic subunit 
from the complex. We find that short and flexible tethers contribute to a decrease 
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in the average characteristic time of binding, allowing the catalytic subunit to 
spend more time in a bound state with the substrate, which yields faster 
characteristic times of phosphorylation. We further demonstrate that release of 
the catalytic subunit from the AKAP complex abrogates the effect of tethering, 
with characteristic times of phosphorylation similar to non-AKAP bound PKA. The 
data demonstrates that AKAPs likely do not release the catalytic subunit in 
directing PKA phosphorylation to AKAP bound substrates. In combination with 
the changes in characteristic time of phosphorylation that are driven by tether 
structure, this work indicates that the purpose of AKAPs may be to increase the 
efficiency of phosphorylation of particular AKAP substrates. 
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Introduction 
 The second messenger cAMP and its effector, cAMP-dependent protein 
kinase A (PKA), constitute a ubiquitous cell-signaling network responsible for the 
phosphorylation of numerous substrates. Recent experimental methods that 
employ mass spectrometry identify 112 potential PKA substrates in a single cell 
type (5). The existence of such an abundance of PKA substrates in a single cell 
highlights the importance of signal compartmentation within the cAMP-PKA 
signaling pathways. Achieving phosphorylation of specific substrates in response 
to an extracellular stimulus is complicated by the rapid diffusion of cAMP and 
also by diffusion of the PKA catalytic subunit. The vast majority of evidence 
regarding PKA activation indicates that binding of cAMP to allosteric sites on the 
regulatory subunits results in the simultaneous activation and release of the 
catalytic subunit (10). The co-discoverer of cAMP, Ted Rall, once said that this 
scheme presents “…the unsatisfying picture of the catalytic subunit of protein 
kinase swimming about, happily phosphorylating a variety of cellular constituents 
whether they need it or not”(98).  
However, it is clear that there is great specificity in PKA phosphorylation 
dynamics. It has been known since the late 1970’s that cAMP-PKA signaling is 
actually compartmentalized. Stimulation of the β-adrenergic receptor in 
cardiomyocytes was shown to the activate glycogen phosphorylase, while 
stimulation of the PGE1 receptor did not, even though both receptors signal via 
cAMP and PKA (8). The discovery of A Kinase Anchoring Proteins (AKAPs) has 
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provided at least a partial explanation of signal compartmentation. This class of 
proteins coordinates a multi-protein signaling microdomain by co-localizing PKA 
with specific substrates and additional effectors like phosphodiesterase, 
adenylate cyclase, and phosphatase (29). The ability of an AKAP to coordinate 
such a multi-protein signal complex allows for the local production and 
degradation of cAMP, thereby spatially restricting PKA activation. Co-localization 
of PKA with its substrates in this manner is hypothesized to confer specificity of 
phosphorylation by increasing the local concentration of PKA. While achieving a 
high local concentration of PKA via anchoring to a specific substrate in a 
particular location is straightforward, the result of this mechanism following PKA 
activation and release is less obvious. Since the activated catalytic subunit is 
freely diffusible, it may diffuse to and phosphorylate other substrates in the same 
manner expected for the AKAP bound substrate. While phosphorylation of non-
local substrates may be inhibited by the presence of protein kinase inhibitor (PKI), 
a pseudosubstrate inhibitor of PKA, it must be acknowledged that PKA will not 
necessarily diffuse to and phosphorylate its associated substrate even if released 
in close proximity of its substrate.  Thus, these data call into question the 
mechanism of PKA scaffolding.  
 In contrast, recent evidence has surfaced that PKA is not released 
following stimulation and is able to maintain catalytic activity while bound to its 
regulatory subunit (50, 52).  The ability of PKA to phosphorylate its substrates 
while remaining bound to the AKAP complex would provide for a much more 
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convincing hypothesis regarding specificity of substrate phosphorylation.  This 
novel mechanism of PKA activation has recently been investigated by cryo-EM 
using AKAP7γ as a model system.   The AKAP7γ-PKA complex has been 
demonstrated to posses a remarkable amount of conformational flexibility owing 
to the intrinsically disordered tether region of the PKA regulatory subunits (52). 
This tether restricts the catalytic subunit to space within ~16nm of the AKAP-PKA 
interface. Truncation of the tether was shown to increase substrate 
phosphorylation relative to phosphorylation with the WT tether length. It was 
further demonstrated that following stimulation with the β-adrenergic agonist 
isoproterenol, the catalytic subunit remains within the AKAP complex. These 
results suggest that the tether physically constrains PKA to the location of the 
substrate during phosphorylation and that the structure of the tether is an 
important determinant of substrate phosphorylation. Importantly, these findings 
suggest that scaffolding of PKA to substrates by AKAP may not function as 
currently hypothesized. 
Using a computational approach, we sought to provide a mechanistic 
explanation for the results of Smith et al by determining how tether length and 
flexibility are able to affect phosphorylation. Additionally, we aimed to investigate 
the effect of releasing the catalytic subunit on the rate of substrate 
phosphorylation in order to demonstrate whether or not the current hypothesis 
regarding AKAP function is reasonable. We used Langevin Dynamic (LD) 
simulation to explore the effect modulating the length and flexibility of the PKA 
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tether region on phosphorylation of AKAP complex bound substrate. Our work 
demonstrates that shorter and more flexible tethers allow the catalytic subunit to 
interact with its substrate more often, resulting in higher rates of phosphorylation. 
Furthermore, our simulations of catalytic release from the AKAP complex 
demonstrate that anchoring PKA to its substrate does not reliably direct the 
catalytic subunit to substrates within the complex if it is released from the 
complex. This suggests that to obtain the substrate specificity seen in multiple 
experimental models, PKA must retain its holoenzyme conformation.  Our 
findings strongly support emerging evidence that the PKA catalytic subunit is 
retained within the AKAP-PKA complex. Interestingly, the same mechanism that 
explains substrate specificity of the AKAP complex also seems to confer high 
catalytic efficiency, helping to explain the observation that AKAPs increase the 
speed of substrate phosphorylation (26). This work lends new meaning to the 
idea of local concentration that better explains the ability of AKAPs to control 
substrate specificity. 
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Methods 
Langevin Dynamic Modeling 
LD simulations were carried out using Langdyn, novel software written by Dr. 
Paul Michalski. Langdyn is an appropriate modeling platform when the molecules 
in the system can be described in a coarse-grained manner as a set of 
biochemically distinct spherical sites connected by stiff links. The AKAP-PKA 
complex is well described in this manner. Models that seek to describe finer 
details, such as the motion of individual amino acids, are more appropriately 
simulated with molecular dynamics, while models with less detail will run faster 
with other solvers. 
Molecules are constructed in the graphic user interface in a three-step 
process. First, the types of sites in the molecule are defined. For the AKAP-PKA 
complex, there are five types of sites: an anchor, which is necessary for linking 
molecules to a membrane, substrate, AKAP_R (AKAP bound to the regulatory 
subunit dimer), R_C (regulatory subunit bound to the catalytic subunit), and flex 
links that allow us to modulate flexibility of the regulatory subunit tether. Each 
type can possess an arbitrary number of internal states, which can be associated 
with a set of biochemical reactions (reactions are described below). For example, 
substrate is assigned two states, unphosphorylated and phosphorylated. Each 
type also has an associated physical size, diffusion constant, and color (for 
visualization purposes).  
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Secondly, sites are added to the molecule, and each site is assigned one 
of the previously defined types. To construct the AKAP-PKA complex we add a 
minimum of seven sites: an anchor, substrate, AKAP_R, two flex links, and two 
R_C. Physically, sites are modeled as impenetrable spheres in order to 
accurately capture excluded volume effects. 
Lastly, links are added to connect the sites to each other. Each site can be 
linked to an arbitrary number of other sites in either two or three-dimensions. The 
only requirement is that sites cannot overlap. Links are stiff and thus define an 
inter-site distance, but are free to rotate around the sites. For example, a 
triangular molecule with three sites will not maintain its geometry in the simulation 
with only two links, but will if a third bond is added to enforce a distance between 
the two outer sites. Links are only used to control the distance between sites and 
do not occupy physical space, and both sites and other links are free to pass 
through a link. Excluded volume is only enforced by sites. 
 
Geometry 
Langdyn currently only supports a rectangular geometry with reflecting 
boundary conditions. The rectangular geometry is partitioned into an extra-
cellular space, a planar membrane, and an intracellular space. The size of the 
membrane and the depths of the intra- and extra-cellular spaces are user defined. 
Future versions of Langdyn will support a wider variety of geometries. 
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Particle Motion: Diffusion and Constraints Due to Binding 
Particle motion is influenced by two classes of forces: random forces that 
lead to diffusional motion, and inter-particle forces that impose the constraints 
from intra- and inter-molecular bonds. These forces are incorporated in the over-
damped Langevin equation (1) (99),  
 1         𝜁𝑣 = 𝐹rand + 𝐹bonds  
where 𝜁 is the coefficient of viscous friction, 𝑣 is the particle velocity, and 𝐹rand 
and 𝐹bonds represent the random forces and the total force of bonds. The random 
forces are guaranteed to recapitulate the desired diffusion provided they are 
chosen from normal distribution with variance 
 2        𝐹rand(𝑡) ∙ 𝐹rand(𝑡′) = 2𝑛𝑑𝐷𝜁2  𝛿(𝑡− 𝑡′)  
where D is the desired diffusion coefficient, 𝑛! is the dimension of the system 
(here 𝑛! = 3), and the delta function simply states that the random force is 
uncorrelated in time. The bonds are modeled as stiff springs,  
 3       𝐹bonds = 𝑘𝑖   𝑟𝑖 − 𝑟0,𝑖   𝑟𝑖𝑖   
where the sum runs over all bonds, 𝑘! is a spring constant, 𝑟! is the unit vector 
pointing from the particle to the neighbor with which it shares a bond, 𝑟! is the 
current inter-particle distance, and 𝑟!,! is the equilibrium bond distance. The exact 
value of the spring constant is not important, provided the spring is stiff enough to 
keep sites near the expected distances but not so stiff that accurate motion 
requires unreasonably small time steps. In Langdyn all bonds have a spring 
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constant that allows us to use time steps on the order of 1 to 100 ns for 
biologically relevant diffusion constants. 
 
Reactions 
Zeroeth-order. Langdyn supports particle creation reactions, which are 
often used to buffer the concentration of a species. Given a macroscopic creation 
rate, 𝑘create, with units µM/s, a single molecule is added to the system at each 
time step with probability 𝑘create𝑉𝑑𝑡, where 𝑉 is either the intra- or extra-cellular 
volume depending on the location of the molecule.  
First-order. Langdyn supports two general types of first order reactions, 
both of which are described by a reaction rate, 𝑟, with units s-1, and which occur 
at each time step with probability 𝑟𝑑𝑡. These are: 1) Bond dissociation reactions. 
When a dissociation reaction occurs the bond is simply removed from the system. 
2) Internal state transitions. These describe the transitions between the internal 
states of each site, as defined by the type of that site. The probability of these 
transitions can depend on the identities of binding partners or the states of other 
sites in the same molecule. The former dependency would be used to prevent a 
transition from an unphosphorylated to a phosphorylated state unless the site is 
bound to a kinase. The latter dependency can be used to model allosteric 
interactions.   
Second-order. Langdyn supports binding reactions between two sites. A 
bond is modeled by the creation of a new link between the reacting sites. The link 
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modeled identically to the links which hold molecules together, except it has an 
associated off rate which controls molecular dissociation. Particle-based 
simulations often use the Smoluchowski approach (100) to model bimolecular 
reactions, but such an approach is incompatible with excluded volume. Instead, 
we modified the approach described in Ref. (101) to account for excluded volume. 
Each site is associated with two radii, the physical radius, 𝜌! (i=1,2), which is 
defined in molecule construction and enforces excluded volume, and a slightly 
larger reaction radius, 𝑅! . Two reactive sites undergo a binding reaction with 
probability 𝜆  𝑑𝑡 per time step when their reaction radii overlap. The reaction rate 𝜆 
is related to the macroscopic on rate, 𝑘on, with units of 𝜇𝑀!!𝑠!!, through 
 4         𝑘on = 4𝜋𝑅𝐷 1− 𝑟!𝑅 𝜌 cosh 𝑅 − 𝜌 /𝑟! +   𝑟! sinh 𝑅 − 𝜌 /𝑟!     𝑟! cosh 𝑅 − 𝜌 /𝑟! +   𝜌 sinh 𝑅 − 𝜌 /𝑟!   
where 𝑟! = 𝐷/𝜆, 𝐷 = 𝐷! + 𝐷!, 𝜌 = 𝜌! + 𝜌!, and 𝑅 = 𝑅! + 𝑅!.   
The AKAP-PKA complex model consisted of a single molecule composed of five 
types with a structure based on the published geometry of the complex as 
detailed in the results (52). For each model variant, a 1sec simulation of a single 
complex in a 50nm3 volume was run 500 times on a high performance computing 
cluster. The phosphorylation state of the complex was recorded at 10ms intervals 
yielding 100 data points per simulation. 
 
	   93 
Data reduction and analysis 
 Data reduction and analysis was performed using custom scripts written in 
Python using the SciPy library. To determine the characteristic time of binding or 
phosphorylation, 500 runs of a single model were grouped into sets of 50 runs 
and the average for the unbound or unphosphorylated state was taken at each 
time point. Since there is only 1 molecule per simulation, this produces an 
exponential decay from 1 to 0 as the average state of the molecule transitions 
from completely unbound or unphosphorylated to completely bound or 
phosphorylated. The resulting 10 sets of averaged data produced from the 500 
runs were then fit with a single exponential model (Eq. 5), where y is the average 
value of the state, b is the inverse of the characteristic time of binding or 
phosphorylation, and t is time. 5   𝑦 = 𝑒!!∗! 
The mean and standard deviation of the characteristic times for the 10 sets of 
averaged data are reported. 
 To determine the average time spent in the bound state for a given set of 
simulations, the total number of data points in which the complex existed in a 
bound state was determined for each run. The time spent in the bound state was 
then averaged for all 500 simulations of a particular model. The mean and 
standard deviation are reported for each model variation. 
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Analytical Prediction of Phosphorylation Rate 
Expected catalytic rates for PKA were calculated using the standard 
Michaelis-Menten equation (Eq. 6), where V is reaction velocity (mm/s), kcat is the 
catalytic rate (s-1), Km is the Michaelis constant (mM), and [E] and [S] are the 
enzyme and substrate concentrations (mM) respectively. 
6   𝑉 =   𝑘!"# 𝐸 [𝑆]𝐾𝑚 + [𝑆]  
This model of ensemble enzymatic reactions has been shown, both theoretically 
and experimentally, to hold for single molecule reactions (102, 103). The 
Michaelis constant was calculated from the following equation (Eq. 7), where kcat 
is the catalytic rate and kf and kr are the reverse and forward rate constants for 
the binding of enzyme to substrate. 
7   𝐾𝑚 =   𝑘! + 𝑘!"#𝑘!  
Since the volume accessible to the catalytic subunit is limited by the tether length 
(distance from center of the AKAP_R subunit to center of RC), the concentrations 
of E and S were adjusted to a spherical volume with a radius equal to the tether 
length. Given the adjusted concentrations and known kcat, kf and kr, we determine 
V (µM/s). The reaction velocity is then converted to catalytic rate by dividing 
through by the adjusted enzyme concentration. 
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Results 
Modeling the AKAP-PKA complex 
Simulation of substrate phosphorylation within the AKAP-PKA complex is 
a multifaceted task that necessitates accounting for structural details in addition 
to standard reaction kinetics. Such structural detail generally falls within the realm 
of molecular dynamics simulation; however, this method is very computationally 
expensive and would not be appropriate given the time-scales of the binding and 
phosphorylation reactions in question. Similarly, stochastic simulation of this 
reaction network could be accomplished using a tool like Smoldyn. Yet, this 
method does not account for space filling of molecules and the spatial resolution 
of this type of modeling would be pushed to its absolute limits. Our novel 
simulation software takes advantage of Langevin Dynamics (LD) to provide a 
meso-scale modeling platform that accounts for coarse-grained structural details 
and is capable of simulating the AKAP-PKA complex with the appropriate spatial 
resolution. 
In the LD software, molecules are constructed from spheres or sites of a 
particular type and springs or links. Our model of the AKAP-PKA complex is 
constructed of 5 molecular types: anchor, substrate, AKAP_R, linker, and RC 
(Fig 4.1A). The geometry of the AKAP complex is based upon the 3D 
reconstruction from Smith et al (52). In order to link the molecule to the 
membrane it is necessary to include an anchor, which represents the membrane 
insertion of our target substrate. The interface of AKAP with the  
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Figure 4.1 Langevin Dynamic Model of the AKAP-PKA complex. A) Structure of the AKAP-PKA 
complex with labeled site types. B) A total of 190 model variants were created that vary in both 
flexibility (left) and length (right). C) Model Parameters. Characteristics assigned to each site type 
(above) and kinetic parameters of each reaction network (below). 
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dimerization/docking domain of the PKA regulatory subunits is represented by 
AKAP_R, and the catalytic subunit bound to the inhibitory domain of the 
regulatory subunit is represented by RC. The diffusion rates of the molecule 
types are based upon standard rates for cytosolic and membrane bound proteins. 
The diffusion rate of GFP in chinese hamster ovary cells has been measured at 
27µm2/s (104). Although our diffusion coefficient for RC is roughly one order of 
magnitude less than that of GFP, simulations with diffusion coefficients varying 
from 3-15µm2/s show no effect on the characteristic time of phosphorylation (data 
not shown). Diffusion rates for transmembrane proteins are generally less than 
0.1µm2/s. Since links between sites are stiff, we create flexibility in the link 
between AKAP_R and RC by adding dummy sites called flex links. By increasing 
the number of links in the tether, we are able to increase the flexibility. To 
simulate the effects of tether length and flexibility on the rate of substrate 
phosphorylation, we created a series of models in which the total length of the 
tether (center of AKAP_R to center of RC) is varied as well as the number of link 
segments (Fig 4.1B). A total of 190 model variations were created with lengths 
varying by increments of 1nm from 9.25m to 25.25nm, and flexibility ranging from 
a minimum of 2 link segments to a maximum of 14 link segments. For shorter 
tether lengths, the maximum number of link segments is limited by the number of 
flex link sites that could be fit within the tether length. The properties assigned to 
each site type as well as the kinetics of the simulated reactions are outlined in 
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figure 4.1C. The reaction kinetics are based on electronic measurements of 
single-molecules catalysis by PKA (105). 
 
AKAP-PKA complexes with shorter more flexible tethers display faster 
characteristic times of enzyme-substrate binding and spend more time in the 
bound state on average 
Phosphorylation of substrates by PKA occurs in a multi-step process 
involving binding of both ATP and substrate prior to catalysis. Due to the high 
cellular concentration of ATP, it is reasonable to model this process in two steps: 
1) binding of PKA and substrate, 2) phosphorylation of substrate. Given that the 
catalytic rate of PKA is unlikely to be altered by the structure of the tether, we 
hypothesized the any changes in the apparent rate of catalysis would be driven 
by altered binding of the catalytic subunit with its substrate.  
We first examined the characteristic time of binding (CTB), defined as the 
time from simulation start to the first binding event (Fig 4.2A). For this set of 
simulations, only the forward binding reaction was included (Fig 4.1C). CTBs 
varied from a minimum of 0.445ms ±0.078 to a maximum of 3.812ms ± 0.563. In 
general, shorter and more flexible tether lengths displayed faster CTBs. The 
effect of varying tether length is most dramatic for the least flexible model 
variations, while there is virtually no difference in the CTB with change in length 
for the most flexible model variations. Similar trends are seen with changes in 
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flexibility at the extremes of the model variations. Changes in tether flexibility 
affect CTB least for short tether lengths and most for longer tether lengths. 
Since the catalytic rate of PKA (21s-1) is much slower than kr for binding of 
catalytic to substrate (350s-1), binding and unbinding of the catalytic subunit and 
substrate is expected to occur multiple times prior to phosphorylation on average. 
Model variations allowing catalytic and substrate to exist in a bound state for a 
greater fraction of total simulation time were hypothesized to have an increased 
probability of substrate phosphorylation and hence faster characteristic times of 
phosphorylation (CTP). We determined the average fraction of time spent in the 
bound state (FTB) by simulating binding and unbinding of catalytic subunit and 
substrate without allowing substrate phosphorylation (Fig 4.1C). The average 
FTB ranged from 0.415 ±0.05 to 0.847 ±0.043 with variations following the same 
trends as for characteristic times of binding (Fig 4.2B). Since the kf and kr remain 
unchanged for all model variations, the differences in the FTB must result from a 
change in the apparent forward rate of binding. 
Increases in apparent kf of binding and average time spent in the bound state 
translate to decreases in characteristic times of phosphorylation 
 The variation in the CTBs and FTBs suggested that changes in the tether 
length and flexibility were likely to affect substrate phosphorylation. Model 
variations displaying an increased FTB were expected to display shorter CTPs 
because this should increase the probability of phosphorylation. We determined 
the CTP by simulating binding and unbinding of the catalytic subunit to substrate,  
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Figure 4.2 Tether length and flexibility modulate binding of the catalytic subunit to substrate. A) 
Characteristic times of binding with varied tether length and flexibility. Simulations were run for  
only the binding reaction of catalytic and substrate (no unbinding). Each data point represents the 
average time from simulation start to binding of catalytic and substrate for 10 sets of 50 
simulations ±1SD. B) Average fraction of time that the catalytic subunit and substrate spend in the 
bound state. Binding and unbinding of the catalytic subunit with substrate were simulated over the 
course of 1s. Each data point represents the average fraction of time(s) ±1SD for 500 simulation 
runs. 
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and irreversible substrate phosphorylation (Fig 4.1C). CTPs varied from a 
minimum of 0.054s ±0.004 to a maximum of 0.119s ±0.012 (Fig 4.3A).  As 
expected, the general trend was that models with shorter and more flexible 
tethers to displayed the fastest CTPs. 
 In order to verify that the CTPs predicted from the LD simulations are 
realistic, we used the quasi-steady state Michaelis-Menten model of enzyme 
kinetics to generate an analytical prediction for comparison. While the 
assumptions implicit in the original derivation of Michaelis-Menten kinetics are not 
valid for our single molecule simulations, it has been demonstrated both 
theoretically and experimentally that this model is a good approximation of 
reaction velocity even for single enzyme kinetics (102, 103). In order to determine 
the expected CTP using the Michaelis-Menten model, we adjusted the 
concentrations of the catalytic subunit and substrate by considering their local 
concentrations to be the number of molecules within a spherical volume having a 
radius equal to the length of the tether. The predicted reaction velocity was then 
converted to a catalytic rate (inverse of CTP) by dividing by the local 
concentration of the catalytic subunit. The analytical predictions of CTP agree 
reasonably well with the LD simulation results for models with the most flexible 
tethers for each length (Fig 4.3B). The characteristic times of phosphorylation 
predicted by Michaelis-Menten kinetics are roughly twice as fast as those 
predicted by LD simulation. This deviation from the analytical prediction is a 
result of anchoring of the substrate to the membrane, which prevents its free  
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Figure 4.3 Tether length and flexibility modulate the rate substrate phosphorylation. A) 
Characteristic times of phosphorylation with varied tether length and flexibility. Simulations 
included binding and unbinding of the catalytic subunit with substrate as well as irreversible 
substrate phosphorylation. Each data point represents the average time from simulation start 
phosphorylation of substrate for 10 sets of 50 simulations ±1SD. B) Comparison of characteristic 
times of phosphorylation for the most flexible model variations at each length to characteristic 
times of phosphorylation predicted by Michaelis-Menten kinetics with adjusted concentrations of 
enzyme and substrate. A second set of LD simulations of the most flexible tether variations with 
only one catalytic subunit was run for each length for comparison to the analytical predictions. 
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diffusion within the same volume occupied by the catalytic subunits thereby 
reducing the CTP. 
 
Release of the catalytic subunit abrogates the effect of PKA tethering for a single 
AKAP-PKA-substrate complex 
 It is well established that the primary function of AKAPs is to 
compartmentalize cAMP/PKA signaling. Numerous studies have demonstrated 
that disruption of AKAP binding to a particular substrate leads to a decrease in 
phosphorylation or change in the expected physiologic response (23, 24, 35). 
How AKAPs direct PKA phosphorylation to AKAP complex bound substrates 
remains unknown as the widely accepted mechanism of signaling requires the 
release of the catalytic subunit (10). In light of our findings that the structure of 
the regulatory subunit tether alters phosphorylation kinetics and evidence that the 
catalytic subunit is not released from the AKAP-PKA complex, we simulated the 
release of the catalytic subunit from the complex to determine its effect on 
substrate phosphorylation. 
 To simulate the effect of releasing of the catalytic subunit on 
phosphorylation of AKAP complex bound substrate, we removed the tether from 
the model and initialized the simulations with two catalytic subunits positioned 
within 16.25nm of AKAP_R (WT), within 5nm of the substrate (close), or 
randomly throughout the 50nm3 simulation space (Fig 4.4A). Positioning of the 
catalytic subunits at the maximum distance from AKAP_R that could be expected 
for the wild type geometry lead to an average CTP of 0.193s ±0.025. Interestingly,  
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Figure 4.4 Simulation of release of the catalytic subunit from the AKAP-PKA complex. A) 
Release of the catalytic subunit was simulated by removing the tether from the model and 
initializing the simulations with the catalytic subunits positioned either 16.25nm from substrate, 
5nm from substrate or randomly within the simulation space. The characteristic times of 
phosphorylation are compared to the analytical prediction for two catalytic subunits and a single 
substrate within a 50nm3 volume. B) Predicted change in characteristic time of phosphorylation 
(CTP) and mean squared distance of PKA as two catalytic subunits diffuse from their initial 
position within the AKAP complex. 
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positioning the catalytic subunits close enough to the substrate for binding to 
occur in the first time step of the simulation did not improve the CTP (0.208s 
±0.031). Positioning the catalytic subunits within the space available to tethered 
PKA also did not improve the CTP compared to random positioning of the two 
catalytic subunits within the simulation space (0.210s ±0.026). These results 
suggest that anchoring of PKA to substrates by AKAP is not an effective method 
of directing PKA phosphorylation to the bound substrate if the catalytic subunit 
must be released in order for phosphorylation to occur. Regardless of how close 
the catalytic subunits are positioned upon release, the CTP does not differ from 
that of randomly placed catalytic subunits. Once released, the CTP is equal to 
the expected CTP for catalytic subunits with access to the entire compartment 
that it is located in. Even for the very small volume of our simulation space, the 
CTPs for catalytic release are much slower than the rates for all tether models 
with the WT length (min 0.059s ±0.007 to max 0.087s ±0.011). 
 For some cell types, like the cardiac myocyte, AKAP directs 
phosphorylation to substrates that are distributed throughout the cytosol, thus the 
released catalytic subunit is not confined to a small compartment as in our LD 
simulations. In this case, the CTP for the substrate that the catalytic subunits 
were initially tethered to would decrease rapidly due to diffusion away from the 
initial location. Using our Michaelis-Menten analytical method, we predicted the 
change in the CTP over time as the catalytic subunits diffuse away from their 
initial position (Fig 4.4B). The change in concentration of catalytic subunit over 
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time was determined for a spherical volume with a radius equal to the mean 
squared displacement (MSD) of the catalytic subunit (Eq. 8).  8   𝑀𝑆𝐷 =    6𝐷𝑡 
Once released, the catalytic subunit quickly diffuses away resulting in a drastic 
increase in the CTP (Fig 4.4B). The increase in CTP is such that after a few ms it 
would be unreasonable to expect that the catalytic subunit would return to its 
initial location and phosphorylate the AKAP bound substrate. Importantly, this 
demonstrates that outside of a small compartment like the dendrite of a neuron, 
release of the catalytic subunits from the AKAP-complex would be even less 
effective at achieving phosphorylation of complex bound substrates than for our 
small volume LD simulations. 
 
Discussion 
 The importance of AKAPs in compartmentalization of cAMP-PKA signaling 
has been well demonstrated (23, 24, 35). It is now widely accepted that AKAPs 
not only tether PKA to a particular substrate, they also co-localize with other 
signal effectors like adenylate cyclase and phosphodiesterase, thereby acting to 
coordinate a signaling microdomain (29). Even though great progress has been 
made in our understanding of the spatial coordination of signaling components by 
AKAPs, how these AKAP complexes operate at the single molecule level 
remains poorly understood. While AKAPs are named for their ability to direct PKA 
phosphorylation to a particular substrate, we still do not have a molecular 
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mechanism to explain how this occurs. This phenomenon is further complicated 
by years of evidence suggesting that activation of PKA requires the release of a 
freely diffusible catalytic subunit. However, recent evidence suggests that in the 
cell, the catalytic subunit is capable of phosphorylating AKAP complex bound 
substrates without being released (50, 52). It has been further demonstrated that 
structure of the PKA regulatory subunit tether is an important determinant of 
substrate phosphorylation. 
  We used Langevin Dynamic simulation of the AKAP-PKA complex to 
further explore the contribution of the structure of the PKA regulatory subunit 
tether to substrate phosphorylation with the hope of gaining additional 
mechanistic insight into the function of the AKAP-PKA complex. Our work first 
demonstrates that modulation of the tether length and flexibility changes the CTB 
between the catalytic subunit and substrate, with shorter and more flexible 
tethers tending to have faster CTBs (Fig 4.2A). The change in CTB, resulting only 
from alterations in tether structure, modulates the fraction of time that catalytic 
subunit and substrate spend in a bound state (Fig 4.2B). This translates into 
changes in the CTP, with models having higher FTBs showing decreased CTPs 
(Fig 4.3A). Since our primary interest is to understand how AKAPs direct PKA 
phosphorylation to AKAP bound substrates we also simulated how the release of 
the catalytic subunit from the complex affects phosphorylation. Positioning of the 
catalytic subunits within the space available to the WT tether length does not 
result in CTPs that are significantly different from those positioned randomly 
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throughout the simulation space, indicating that AKAPs do not effectively direct 
PKA phosphorylation to AKAP bound substrates if the catalytic subunits are 
released (Fig 4.4A). We further demonstrate that in a large compartment like the 
cytosol, release of the catalytic subunit from the AKAP complex would lead to its 
quick diffusion away from the anchored substrate without phosphorylation (Fig 
4.4B). The results of our simulations suggest that in the cell the catalytic subunit 
is likely not released, as this would lead to a significant decrease in the efficiency 
of phosphorylation of AKAP complex bound substrates. 
 The decreased CTB and increased FTB for shorter tether lengths reflect 
an increased apparent forward rate of binding. Since the rate constants (kf and kr) 
remain the same for all model variations, the changes in the apparent forward 
rate indicate that the structure of the tether influences the probability of 
interaction of the catalytic subunit with its substrate. As the regulatory subunit 
tether is shortened, the space available to the catalytic subunit decreases, 
thereby increasing the probability that it will encounter and bind to the substrate 
as long as the substrate remains accessible. The increased probability of 
interaction has previously been interpreted as resulting from an increase in the 
local concentration of the catalytic subunit. While this interpretation allows us to 
easily predict the CTP via the Michaelis-Menten model, the changes in CTB, FTB, 
and CTP result from differences in structure, not concentration, and thus are 
more correctly thought of as changes in apparent forward rate constant. The 
flexibility of the tether likely modulates accessibility of the space within the 
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spherical volume defined by the tether length. For lengths that allow access to 
substrate in the most extended conformation, flexibility has little impact on CTB 
or FTB. With longer tethers that must deform in order to reach the substrate, 
changes in flexibility have much more impact on the CTB and FTB (Fig 4.2). 
Although differences in the regulatory subunit tether length are only expected 
with interspecies variation, positioning of substrates within the AKAP complex 
does vary and would affect rates of interaction similarly. One potential caveat to 
bear in mind is our inability to account for rotational conformation. In reality, 
phosphorylation of substrates by the catalytic subunit would require precise 
alignment of the catalytic cleft with the substrate. It may be possible that a certain 
degree of tether stiffness could actually facilitate phosphorylation by maintaining 
proper alignment of the catalytic subunit and substrate. 
 Changes in the CTP with tether length and flexibility are most likely driven 
by changes in the apparent forward rate of binding. Although the idea of a local 
concentration offers a simple method for analytical prediction of the CTP, the 
actual concentration of the catalytic subunit and substrate do not change. 
Considering the changes CTB and FTB as resulting from changes in apparent kf 
rather than concentration offers interesting insight into the changes in CTP and, 
more generally, the function of AKAPs. Increasing the kf of the binding reaction 
results in a decrease in the Michaelis constant (Methods Eq. 7), which translates 
into an increase in the velocity of the phosphorylation reaction according the 
Michaelis-Menten model (Methods Eq. 6). Interestingly, such change in the Km 
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also suggests that the efficiency of phosphorylation is improved according to the 
following equation (Eq. 9), where E is catalytic efficiency:  
9   𝐸 = 𝑘!"#𝐾𝑚  
 
This interpretation of the change in CTP resulting from changes in tether 
structure is a previously unconsidered, but incredibly important advancement in 
our understanding of the function of AKAPs. It suggests that AKAPs don’t simply 
increase the speed or magnitude of phosphorylation by increasing local 
concentration of PKA, rather AKAPs increase the efficiency of phosphorylation of 
the AKAP complex bound substrate. 
 The increase in efficiency of phosphorylation of AKAP bound substrates is 
best illustrated by comparing the CTPs of tether models with those from our 
models of catalytic release. For models involving catalytic release, the CTP is at 
minimum 2.5-fold slower than the slowest tether model. Given the small size of 
our simulation space and our evidence that the rate of substrate phosphorylation 
depends on the size of the compartment for free catalytic subunit, the increase 
CTP is likely to be much more dramatic for most AKAP-PKA signaling systems in 
the cell.  
Our new hypothesis regarding the function of AKAPs also offers some 
interesting interpretations of old data. While the definition of local concentration of 
PKA in the previous hypothesis is somewhat ambiguous, we will define it as 
concentration of PKA within the compartment of the AKAP-PKA complex. 
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Experiments in which AKAP-substrate binding has been disrupted demonstrate a 
reduction in phosphorylation of the intended substrates (24, 27). While this was 
attributed to de-localization of PKA and hence, a decrease in local concentration, 
our evidence indicates that such delocalization would also occur upon activation 
of PKA if the catalytic subunit is released from the complex in order for 
phosphorylation to occur. The effect of tethering the catalytic subunit to its target 
is even better demonstrated through the use of the FRET sensor AKAR (A 
Kinase Activity Reporter 2), which measures PKA phosphorylation real time in 
cells (25). Addition of the PKA binding site to the AKAR2 construct resulted in 
FRET signal changes following stimulation that were both faster and of higher 
magnitude when compared to AKAR2 alone (26). Since AKAR2 with or without 
the addition of the PKA binding site is localized only to the cytosol, it is not 
reasonable to assert that there is difference in the local concentration of PKA. 
The sensor is located in the same compartment in both cases and we are not 
forcing redistribution of PKA to a larger space by preventing AKAP localization to 
a particular substrate. Our hypothesis that AKAPs increase the efficiency of 
AKAP complex bound substrate phosphorylation fits very well with this data. Our 
simulation data suggests that the increased rate of phosphorylation, and likely 
the increased magnitude, is what should be expected. Interestingly, we find that 
the kinetics of phosphorylation for released catalytic subunit are too slow to 
mediate some signal processes known to require PKA. The time scale of PKA 
mediated effects on Na2+ channels occur on the order of milliseconds, which 
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according to our LD simulations occurs too quickly to be mediated by the catalytic 
subunit if released from the complex (36).  
Computational analysis of the AKAP-PKA complex using our novel 
software, Langdyn, has led to numerous exciting findings. First, we offer a 
mechanism for the changes in phosphorylation rate seen with alteration in the 
structure in regulatory subunit tether. Second, we present evidence that release 
of the catalytic subunit would likely abrogate the effect of tethering PKA to a 
particular substrate. This evidence suggests that for efficient substrate 
phosphorylation to occur, the catalytic subunit cannot be released. This change 
in the mechanism of phosphorylation also provides us with a partial molecular 
mechanism that explains how AKAPs might direct PKA phosphorylation to AKAP 
complex bound substrates. Finally, we propose an improvement to the 
hypothesis that AKAPs increase the speed and magnitude of substrate 
phosphorylation by increasing local concentration. We hypothesize that AKAPs 
act to increase the efficiency of PKA phosphorylation and suggest that local 
concentration should be thought of as the amount of enzyme and substrate within 
a volume defined by the length of the regulatory subunit tether, rather than within 
a local region or compartment within the cell. This revision of the AKAP 
hypothesis represents a critically important step forward in our understanding of 
PKA signaling. 
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Chapter 5  
Conclusions 
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Since its discovery in 1958 by Sutherland and Rall, much progress has 
been made in our understanding of cAMP signaling. We know that cAMP is 
produced by adenylate cyclase (AC) following activation of G-protein coupled 
receptors (GPCRs) at the cell surface, that the rise in cAMP concentration 
activates signal effector proteins like PKA, exchange protein directly activated by 
cAMP (Epac), and cyclic nucleotide-gated channels, and that this signal is 
terminated by phosphodiesterases (PDEs) that degrade cAMP. It is understood 
that although many different GPCRs use cAMP and PKA to convey their signals, 
this signaling system is compartmentalized primarily through the ability of A-
kinase anchoring proteins (AKAPs) to tether PKA to a particular substrate, thus 
directing its phosphorylation to the intended downstream target (106). We have 
also discovered that many AKAPs are capable of binding to AC, PDE, and other 
signal effectors, thereby allowing AKAPs to coordinate a cAMP-PKA signaling 
microdomain in which all of the necessary components are co-localized (29). 
Much of the work that has been done up to this point has focused upon 
identifying components of the AKAP complex and examining changes in 
physiology when specific components are inhibited or prevented from associating 
with the complex. This has lead us to think of the AKAP complex as a static entity 
in which all of the components necessary for signaling are always present in the 
complex, or at least in a vaguely defined compartment of the target substrate.  
The work presented here forces us to think of the AKAP complex in new 
ways that represent an evolution in our understanding of the function of the 
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AKAP complex. In chapter two, I demonstrated that AKAP7γ is able to bind to 
itself, forming a dimer that has the potential to augment PKA phosphorylation. 
This indicates that in addition to other complex components being present or not, 
the stoichiometry of the AKAP complex is important and impacts the function of 
the complex. In chapter 3, I showed that AKAP7γ binding to PLB is 
phosphorylation-state dependent and that this state dependent mode of binding 
allows small quantities of the AKAP complex to control phosphorylation of large 
quantities of substrate. This work indicates that the AKAP complex is likely not a 
static entity in which AKAP binds to the necessary signal components, recruits 
them to a particular substrate, and remains in a stable complex. The AKAP 
complex is more likely a dynamic structure that may change composition 
continually due to binding and unbinding of components, or may change as a 
result of certain signaling events as we see with the AKAP-PLB interaction. 
Finally, in chapter 4, I added to the accumulating evidence that suggests the PKA 
catalytic subunit does not dissociate from the AKAP complex to phosphorylate its 
substrates. This work also demonstrates the importance of the structure or 
topology of the AKAP complex. While I demonstrated that the structure of the 
PKA regulatory subunit tether alters rates of phosphorylation, AKAPs themselves 
are also flexible structures that may allow for positional variation in 
phosphorylation rates of some AKAP complex components. Overall, this work is 
an important step forward towards understanding how AKAP complexes function. 
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In the following sections I present some final commentary on each of the 
chapters and discuss the potential for future work. 
 
AKAP7γ Oligomerization augments PKA signaling  
 This chapter represents my earliest work and deserves some re-
interpretation in light of the results presented in chapter 4. While I remain 
convinced of the ability of AKAP7γ to form dimers, and potentially higher order 
oligomers that were undetectable by PCH, I no longer believe that release of the 
catalytic subunit is necessary for PKA to phosphorylate its AKAP bound 
substrates. The mechanism of the feed-forward loop that defines activation and 
release of the catalytic subunit was partly a mechanism for dealing with the 
reported high cellular concentration of cAMP (1µM) and very high affinity of the 
regulatory subunit for cAMP. In my initial attempts to model the AKAP complex, 
controlling the activation and release of PKA was problematic. This was primarily 
due to the fact that the published kinetics defining activation and release led 
either to very high baseline activity of PKA, or conversely, made it very difficult to 
get an appropriate response to stimulation of β-adrenergic activity. Evidence 
presented by Martin et al suggested that auto-phosphorylation of the regulatory 
subunit was necessary for the release of catalytic, which provided us with a 
potential way to deal with the problematic activation/release kinetics (51). With 
the kinetics that required higher levels of cAMP for activation of PKA, requiring 
auto-phosphorylation of the regulatory subunit for release of the catalytic subunit 
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generated a feed-forward loop that gave an appropriate response to stimulation, 
and also demonstrated that oligomerization of AKAP7γ could potentiate 
increases in substrate phosphorylation. This hypothesis is still valid if one does 
not accept the emerging evidence that the catalytic subunit is not released from 
the AKAP complex in the cell.  
 Alternatively, if the catalytic subunit is not released from the oligomeric 
AKAP complex, the accelerated kinetics and increased magnitude of 
phosphorylation would depend on the topology of the complex and accessibility 
of each of the catalytic subunits to the complex bound substrate(s). Since PKA is 
also known to alter the activity of other potential components of the complex 
including AC, PDE, and PP1, the presence of multiple catalytic subunits in an 
oligomeric complex could also impact phosphorylation via regulation of cAMP 
production and degradation, or alteration in substrate dephosphorylation kinetics. 
We did not find this to be the case with our current version of the AKAP7γ 
oligomer model. However, a thorough investigation of the impact of 
oligomerization for an AKAP complex in which the catalytic subunit is not 
released would require construction of an entirely different model.  
 To continue this work, the effect of oligomerization of AKAP7γ on substrate 
phosphorylation in live cells needs to be demonstrated. The most direct way to 
assess this is to disrupt oligomerization in the cell and examine the levels of 
substrate phosphorylation pre and post β-adrenergic stimulation. While this could 
be done easily by generating a deletion mutant lacking the self-association sites, 
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these sites overlap with regions that would impact binding of other AKAP 
complex components, including PKA. Though difficult, it may also be possible to 
design reagents that could disrupt oligomerization. Similar to the design of Ht31, 
which dissociates PKA from AKAPs (19), short peptides mimicking the self-
association sites may have a higher affinity for AKAP7γ than itself, resulting in the 
disruption of oligomerization. Alternatively, the impact of having multiple PKA 
molecules in the same complex could be assessed by creating a series of AKAR 
sensors linked to varying numbers of PKA binding sites.  	  
Phosphorylation-state dependent interaction between AKAP7δ/γ and 
phospholamban increases phospholamban phosphorylation 
This work provides an answer to a long standing and important question in 
the field of AKAP and cardiac biology: how does a protein like AKAP7γ, which is 
present in the cell at low concentration, control phosphorylation of a high 
concentration, widely dispersed protein like PLB or troponin. Additionally, this 
work also revives the importance of the AKAP7γ-PLB interaction, which has not 
been published on since 2012 when Jones et al suggested that it does not 
regulate PLB phosphorylation (90). While the computational model presents 
compelling data demonstrating that phosphorylation-state dependent binding of 
AKAP7γ with PLB greatly increases the magnitude of phosphorylation by 
AKAP7γ bound PKA, the next logical step for this work is to demonstrate this 
phenomenon experimentally. The phosphorylation state dependence of AKAP7γ 
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binding to PLB suggests that the complex should be highly mobile in response β-
adrenergic stimulation. This mobility should be demonstrable via fluorescence 
resonance after photobleaching (FRAP). Comparison of the mobility of a GFP 
tagged AKAP7γ could be made a series of cell systems containing either a non-
phosphorylatable PLB (S16A), WT PLB or a phospho-mimetic PLB (S16D). In 
this comparison, it would be expected that AKAP7γ has the lowest mobility in the 
PLB(S16A) system, an intermediate mobility in the WT PLB system, and the 
highest mobility in the PLB(S16D) system. This phenomenon could be further 
explored by examining the mobility of AKAP7γ-GFP in rat neonatal cardiac 
myocytes, which express endogenous PLB, pre and post β-adrenergic 
stimulation. 
The phosphorylation state dependence of AKAP7γ-PLB binding also 
highlights the possibility that other AKAP binding partners also have state 
dependencies. Though controversial, evidence does exist that the affinity of RIIα 
for the PKA binding domains of AKAP7, mAKAP, and AKAP-Lbc is altered by 
RIIα phosphorylation (107). Similar changes in affinity following phosphorylation 
may exist for other AKAPs and their substrates, as well as for other binding 
partners like AC, PDE, etc. Such findings would be a clear indication that AKAP 
complexes are highly dynamic structures. 
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Langevin Dynamic Simulation of AKAP-PKA Complex: Re-envisioning the local 
concentration mechanism for directing PKA phosphorylation 
The work presented in chapter 4 is certainly the most controversial, but 
also has the most exciting implications. The ability of the AKAP-PKA complex to 
retain the catalytic subunit following stimulation of cAMP production provides a 
very clear molecular mechanism that explains not only how AKAPs are able to 
compartmentalize cAMP-PKA signaling, but also indicates that the purpose of 
AKAPs is likely to enhance the efficiency of phosphorylation specific PKA. As is 
the case with most scientific progress, this work leads us to ask nearly as many 
questions as it answers. If the catalytic subunit retains its activity while still bound 
to the PKA regulatory subunit, how does PKA respond to increases in cAMP? 
How can the catalytic subunit phosphorylate substrates if the regulatory subunit 
is bound via the catalytic cleft? Are there specific conditions that determine 
whether or not the catalytic subunit is released? Unfortunately many of these 
questions are unlikely to be answered soon, and will need to wait for advances in 
technology that have not yet occurred. The structure of the entire PKA complex 
has yet to be solved due to the high degree of flexibility of the tether region. To 
capture the conformational changes in the catalytic subunit during a signaling 
event, within the AKAP complex, and in the cell would be an incredibly difficult 
task. 
The most important follow up on this work is to demonstrate in a live cell 
whether or not the catalytic subunit is released in response to β-adrenergic 
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stimulation. This can be accomplished via total internal reflectance fluorescence- 
single particle tracking microscopy (TIRF-SPT).  By tagging the catalytic subunit 
with a photo-switchable fluorophore like mEOS, we can image the population of 
mEOS-catalytic that is recruited to the cell membrane by AKAP and track the 
number of catalytic subunits at the membrane over time, in the presence and 
absence of β-adrenergic stimulation. I have conducted preliminary experiments 
with AKAP79 demonstrating that these experiments are possible. Unfortunately, 
AKAP79 does not stably associate with the membrane, making interpretation of 
catalytic release extremely difficult. This work would be better conducted using 
AKAP7α, which associates with the plasma membrane via post-translational lipid 
modification that allows for insertion into the plasma membrane. AKAP7α should 
form a stable association with the plasma membrane allowing for easier tracking 
of mEOS-catalytic. AKAP7α also offers the additional advantage of not 
associating with any signal components other than PKA and the ion channels 
that are its target substrates, making interpretation of the data much easier. 
Since our preliminary experiments seem to indicate that the catalytic subunit is 
released in response to high concentrations (10µM) of the β-adrenergic agonist, 
isoproterenol, and the direct activator of adenylate cyclase, forskolin, it is 
important to explore the response of the catalytic subunit to lower, more 
physiologically relevant drug concentrations.  
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Concluding Remarks 
Overall, this work offers a number of novel and important ideas regarding the 
function of AKAP complexes. I have demonstrated the importance of both 
stoichiometry and structure of AKAP complex components, and have shown that 
AKAP complexes are likely to be more dynamic than previous thought. While this 
work goes a long way towards answering some major questions in the field of 
AKAP biology, it also provides avenues for important future work. 
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